Table of Contents

PRELIMINARY PROXY STATEMENT—SUBJECT TO COMPLETION

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(A) of

the Securities Exchange Act Of 1934

 

 

Filed by the Registrant  ☒        Filed by a Party other than the Registrant  ☐

Check the appropriate box:

 

☒		Preliminary Proxy Statement
☐		Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐		Definitive Proxy Statement
☐		Definitive Additional Materials
☐		Soliciting Material under §240.14a-12

Amyris, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

☒		No fee required.
☐		Fee paid previously with preliminary materials.
☐		Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

---

Table of Contents

Notice of 2022 Annual

Meeting of Stockholders

 

		Annual Meeting of Stockholders
		Date and Time: Friday, May 27, 2022, 2:00 p.m. Pacific Time		Location: Virtual Meeting: www.proxydocs.com/AMRS		Record Date: Wednesday, March 30, 2022		Mail Date: Notice of Internet Availability of Proxy Materials (“Notice”) will be mailed on or about April 13, 2022

 

Voting Matters   At or before the 2022 Annual Meeting of Stockholders (“Annual Meeting”), we ask that you vote on the following items:     Item 1 Election of three Class III Directors to serve for a three-year term     Item 2 Ratification of the appointment of Independent Registered Public Accounting Firm     Item 3 Approval of amendment to Certificate of Incorporation to increase authorized shares                        Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: our Proxy Statement and 2021 Annual Report are available free of charge on our website at https://investors.amyris.com/annual-reports

How to Vote:

Internet

Mail

Visit www.proxydocs.com/AMRS and use your unique control number found in your Notice, proxy card or voting instruction form to access the voting site

Complete and sign the proxy card or voting instruction form and return it by mail.

Telephone

During the Meeting

Follow the telephone instructions provided in your Notice, proxy card or voting instruction form.

This year’s Annual Meeting of Stockholders will be virtual. For details on how to pre-register and attend the virtual meeting or on how to vote your shares during the virtual meeting, see p. 72, “Questions and Answers about the Annual Meeting and Voting.”

We are using the Internet as our primary means of furnishing proxy materials to our stockholders, instead of mailing printed copies. By doing so, we save costs and reduce our impact on the environment. We will instead mail or otherwise make available to each of our stockholders a Notice of Internet Availability of Proxy Materials, which contains instructions on how to access our proxy materials, and vote, online. The Notice also provides information on how stockholders can obtain paper copies of our proxy materials.   These proxy materials are provided in connection with the solicitation of proxies by the Board of Directors (the “Board”) of Amyris, Inc., a Delaware corporation (referred to as “Amyris”, the “Company”, “we”, “us”, or “our”), for our Annual Meeting. These proxy materials were first sent on or about April 13, 2022 to stockholders entitled to vote at the Annual Meeting.   Your vote is important, regardless of the number of shares of our stock that you own. Whether or not you plan to attend our virtual Annual Meeting, it is important that your shares are represented and voted. We encourage you to submit your proxy as soon as possible by internet, by telephone, or by signing and returning all proxy cards or instruction forms provided to you.   By Order of the Board of Directors

Nicole Kelsey Chief Legal Officer and Secretary April     , 2022

Amyris, Inc. 5885 Hollis Street, Suite 100 Emeryville, California 94608

---

Table of Contents

		Table of Contents

 

 

AMYRIS, INC. 2022 PROXY STATEMENT    1

---

Table of Contents

		Sustainability at Amyris

 

Amyris is deeply committed to sustainability and to protecting the abundance and beauty of nature. Our mission is to accelerate the world’s transition to sustainable consumption. At the heart of what we do is chemistry. By modifying the genetics of yeast strains and fermenting them in sugarcane syrup, we have pioneered the ability to convert basic plant sugars to hydrocarbon molecules. We use what is renewable to recreate what is finite.

Natural biology inspires our technology to create sustainable ingredients. Our technology platform enables us to produce rare, natural molecules that are integral to medications, health, personal care and beauty products that are both safe and effective. Our technology platform provides a scalable way forward in a world where humanity’s demand for the earth’s bounty far exceeds its supply. We do all of this without compromise – to quality, cost and to sustainability. Make good. No compromise.^®

Amyris is a high-growth biotechnology company at the forefront of delivering sustainable solutions that are better for people and the planet. We are focused on the Clean Beauty & Personal Care and Health and Wellness markets through our growing portfolio of consumer brands and as a top supplier of sustainable and natural ingredients to leading global manufacturers and formulators. We have successfully commercialized 13 unique molecules, with dozens more in active development and thousands in the discovery stage in our labs. Our proprietary Lab-to-Market^™ technology platform optimizes learning cycles and improves our predictive success, while accelerating our time to market and reducing cost.

Consistent with our mission, we view Environmental, Social, and Governance (“ESG”) factors as long-term value drivers for our customers, our Company, our community, our stockholders, and all of our other stakeholders.

 

 

ENVIRONMENTAL STEWARDSHIP

Sustainable Ingredients

 

 

AMYRIS, INC. 2022 PROXY STATEMENT    1

---

Table of Contents

Sustainability at Amyris  |  Social Responsibility

 

Environmental Impact and Carbon Footprint

 

 

 

 

2    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Sustainability at Amyris  |  Social Responsibility

 

 

AMYRIS, INC. 2022 PROXY STATEMENT    3

---

Table of Contents

Sustainability at Amyris  |  Corporate Governance

 

 

4    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Sustainability at Amyris  |  Corporate Governance

 

Corporate Governance Strengths

 

Strong independent oversight				Board qualifications and accountability				Board oversight of strategy and risk management
◾		9 out of 11 directors are independent		◾		Diverse Board in terms of tenure, gender, race, ethnicity, experience and skills		◾		Risk oversight by the full Board and Committees
◾		Independent Board Chair and independent Board Committees		◾		Annual Board and Committee self-evaluation		◾		Independent compensation program risk analysis and reporting directly to the LDICC
◾		Executive sessions of independent directors		◾		No poison pill anti-takeover defenses		◾		Audit Committee oversight of cybersecurity

 

 

AMYRIS, INC. 2022 PROXY STATEMENT    5

---

Table of Contents

Sustainability at Amyris  |  Corporate Governance

 

Stockholder Engagement

We recognize the benefits of maintaining a robust dialogue with stockholders, which is why we engage in proactive outreach efforts with certain of our largest stockholders. We solicit feedback from our stockholders on a variety of topics, including our business and growth strategy, corporate governance practices, executive compensation matters, and various other ESG matters. This engagement enables us to build meaningful relationships over time with our stockholders and obtain valuable feedback that helps inform our decisions and our strategy throughout the year.

The following graphic describes our typical stockholder outreach and engagement cycle.

 

 

Following our 2021 annual meeting, we reached out to stockholders who collectively held approximately 20% of our then-outstanding shares to request meetings, and held meetings with each stockholder who accepted our request for engagement.

 

6    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

		Proposal 1

 

Election of Directors

Nominees for Election to the Board of Directors

Under our Certificate of Incorporation and Bylaws, the number of authorized Amyris directors has been fixed at 12, and the Board is divided into the following three classes with staggered three-year terms:

 

◾

Class I directors, whose term will expire at the annual meeting of stockholders to be held in 2023;

 

◾

Class II directors, whose term will expire at the annual meeting of stockholders to be held in 2024; and

 

◾

Class III directors, whose term will expire at this 2022 Annual Meeting of stockholders and who have been nominated for re-election.

In accordance with our Certificate of Incorporation, the Board has assigned each member of the Board to one of the three classes, with the number of directors in each class divided as equally as reasonably possible. As of the date of this Proxy Statement, there are four Class I seats, four Class II seats, and four Class III seats (with one vacancy) constituting the 12 seats on the Board.

At the 2022 Annual Meeting, we are asking our stockholders to vote on the election of three Class III directors, John Doerr, Ryan Panchadsaram, and Lisa Qi to serve until our 2025 annual meeting. The nominees are all current directors of Amyris.

Vote Required and Board Recommendation

Directors are elected by a plurality of the votes present in person or represented by proxy at the meeting and entitled to vote. This means that the three Class III nominees receiving the highest number of affirmative (i.e., “For”) votes will be elected. At the Annual Meeting, proxies cannot be voted for a greater number of persons than the three nominees named in this Proposal 1 and stockholders cannot cumulate votes in the election of directors. Shares represented by executed proxies will be voted by the proxy holders, if authority to do so is not withheld for any or all of the nominees, “For” the election of the three nominees named below. If any nominee is unable or declines to serve as a director at the time of the meeting, the proxies will be voted for a nominee, if any, designated by the Board to fill that vacancy. As of the date of this Proxy Statement, the Board is not aware that any nominee up for election is unable or will decline to serve as a director. If you hold shares through a broker, bank or other custodian, nominee, trustee or fiduciary (an “Intermediary”), you must instruct your Intermediary of record how to vote so that your vote can be counted on this proposal. Broker non-votes will not count toward the vote total for this proposal and therefore will not affect the outcome of this proposal.

 

		The Board recommends a vote “FOR” each nominee.

 

AMYRIS, INC. 2022 PROXY STATEMENT    7

---

Table of Contents

Proposal 1 — Director Biographies  |  Nominees for Class III Directors for a Term Expiring in 2025

 

Director Biographies

Nominees for Class III Directors for a Term Expiring in 2025

 

Director since 2006   Age 70   Board Committees Nominating & Governance Committee (Chair)   Other Current Public Directorships Alphabet Inc. Coursera, Inc. DoorDash, Inc.		John Doerr   Mr. Doerr is Chairman at Kleiner Perkins Caufield & Byers (“KPCB”), a venture capital firm where he has worked since 1980. He currently serves on the board of directors of the following public companies: Alphabet, Coursera, and DoorDash. He previously served as a director of Bloom Energy, Quantumscape and Zynga Inc. Mr. Doerr was previously a director of Amazon from 1996 to 2010. He holds a B.S. in Electrical Engineering and an M.S. in Electrical Engineering and Computer Science from Rice University and an M.B.A. from Harvard Business School.   Key Qualifications   Mr. Doerr’s global business leadership as general partner of KPCB, as well as his outside board experience as director of several public and private companies, enables him to provide valuable insight and guidance to our management team and the Board.

 

Director since 2021   Age 37   Board Committees Audit Committee Leadership, Development, Inclusion & Compensation Committee   Other Current Public Directorships None		Ryan Panchadsaram   Mr. Panchadsaram is a partner at Foris Ventures and serves as an advisor to the Chairman at Kleiner Perkins since 2016. He invests in bold founders and disruptive technologies that are tackling the climate crisis, fixing our healthcare system, and improving the way we live and work. Prior to Kleiner Perkins, Mr. Panchadsaram worked at the White House and served as the deputy chief technology officer for the United States. In 2015, he served as a delegate to the United Nations to launch the Solutions Summit, a grassroots effort to spotlight the work of exceptional innovators around the world tackling the United Nations’ Sustainable Development Goals. Prior to government service, he was a health technology entrepreneur and worked at Microsoft and Salesforce.com. Mr. Panchadsaram holds a Bachelor of Science degree in Industrial Engineering and Operations Research from U.C. Berkeley.   Key Qualifications   Mr. Panchadsaram’s experience with the consumer products industry and innovative technology solutions enables him to provide insight and guidance to our management team and Board.

 

8    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Proposal 1 — Director Biographies  |  Nominees for Class III Directors for a Term Expiring in 2025

 

Director since 2019   Age 50   Board Committees Nominating & Governance Committee   Other Current Public Directorships None		Lisa Qi   Ms. Qi has been a member of the Board since May 2019. Ms. Qi is the founder and chief executive officer of Silver Gift Limited and Daling Xinchao (Beijing) Trading Co., Ltd., which operate the Daling Family e-commerce platform in China.   Key Qualifications   Ms. Qi brings deep knowledge and significant experience in the areas of e-commerce, product branding, sales and management of high-growth companies, which enable her to make a strategic contribution to the Board and provide guidance to the management team in these areas.

 

AMYRIS, INC. 2022 PROXY STATEMENT    9

---

Table of Contents

Proposal 1 — Director Biographies  |  Class I Incumbent Directors with a Term Expiring 2023

 

Class I Incumbent Directors with a Term Expiring 2023
Director since 2022   Age 57   Board Committees None   Other Current Public Directorships CarParts.com CME Group, Inc. First Internet Bancorp		Ana Dutra   Ms. Dutra is the CEO of Mandala Global Advisors Inc., which she founded in 2013, and has over 30 years of experience in P&L management, deal structuring, digital technology, business growth and C-Level business consulting in over 25 countries. Ms. Dutra also currently serves on the board of directors of CarParts.com, CME Group, Inc., and First Internet Bancorp, and certain private companies in the United States and Brazil. Ms. Dutra previously served on the board of directors of Health, Harvest & Recreation Inc. until its acquisition in September 2021. Ms. Dutra holds an MBA from Kellogg School of Management at Northwestern University, a Master’s in Economics from Pontificia Universidade do Rio de Janeiro, and a Juris Doctor from Universidade do Estado do Rio de Janeiro.   Key Qualifications   Ms. Dutra’s extensive experience assisting boards of directors, CEOs and management teams to identify and execute growth strategies through innovation, acquisitions, and new technologies, enables her to provide valuable contributions to our management team and Board.

 

Director since 2012   Interim Board Chair since May 2014   Age 62   Board Committees Audit Committee   Other Current Public Directorships None		Geoffrey Duyk   Dr. Duyk previously served on the Board from May 2006 to May 2011. Dr. Duyk is a partner of Circularis Partners, a technology focused investment firm. Previously, Dr. Duyk served as a partner and managing director of TPG Alternative & Renewable Technologies (TPG ART), a technology focused investment firm (together with its affiliates, “TPG”), from 2004 to 2017. Prior to TPG, he served on the board of directors and was President of Research and Development at Exelixis, Inc., a biopharmaceutical company focusing on drug discovery, from 1996 to 2003. Prior to Exelixis, Dr. Duyk was Vice President of Genomics and one of the founding scientific staff at Millennium Pharmaceuticals, from 1993 to 1996. Before that, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute. Dr. Duyk currently serves on the boards of directors of: Anuvia Plant Nutrients; Concentric Ag Corporation (interim CEO since 2019); and ReGen Holdings Limited, as well as on the Board of Trustees of Case Western Reserve University. Dr. Duyk is also a member of the Institute Board of Directors of the Moffitt Cancer Center where he chairs the Research and Development committee. He is the Chairman of the board of directors of OncoBay Clinical, a private contract research organization (subsidiary of Moffitt Cancer Center). Dr. Duyk serves as a member of Scientific Advisory Board for Lawrence Berkeley National Laboratory (DOE) and a member of the Advisory Board of Innovatus Capital Partners. Dr. Duyk holds a Bachelor of Arts degree in Biology from Wesleyan University and a Ph.D. in Biochemistry and M.D. from Case Western Reserve University.   Key Qualifications   Dr. Duyk’s experience with the biotechnology and pharmaceutical industries, as well as his expertise in technology investing, enables him to provide insight and guidance to our management team and Board.

 

10    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Proposal 1 — Director Biographies  |  Class I Incumbent Directors with a Term Expiring 2023

 

Director since 2019   Age 70   Board Committees Leadership, Development, Inclusion & Compensation Committee (Chair) Nominating & Governance Committee   Other Current Public Directorships 1-800-FLOWERS.COM, Inc. (Chairman) International Game Technology PLC		James McCann   Mr. McCann is the founder and Chairman of the board of directors of 1-800-FLOWERS.COM, Inc., a floral and gourmet foods gift retailer and distribution company founded in 1976, and served as chief executive officer of 1-800-FLOWERS.COM, Inc. from 1976 until June 2016. Mr. McCann also serves on the board of directors of International Game Technology PLC (formerly GTECH S.p.A. and Lottomatica Group S.p.A.) and previously served on the board of directors of Willis Towers Watson PLC (formerly Willis Group Holdings PLC) from 2004 until May 2019 and The Scotts Miracle-Gro Company from 2014 until January 2020.   Key Qualifications   Mr. McCann brings to the Board extensive experience in business leadership, entrepreneurship and innovation, which enables him to assist our CEO in the growth and development of our business.

 

Director since 2018   Age 66   Board Committees Audit Committee (Chair) Leadership, Development, Inclusion & Compensation Committee   Other Current Public Directorships Black Hills Corporation Farmers Edge, Inc.		Steven Mills   Mr. Mills has 40 years of experience in the fields of accounting, corporate finance, strategic planning, risk management, and mergers and acquisitions. He served as Chief Financial Officer of Amyris from May 2012 to December 2013. Prior to joining Amyris, Mr. Mills had a 33-year career at Archer-Daniels-Midland Company (“ADM”), one of the world’s largest agricultural processors and food ingredient providers. At ADM, he held various senior executive roles, including Chief Financial Officer, Controller, and head of Global Strategic Planning. Since 2014, Mr. Mills has served as a consultant and advisor to clients in the private equity, agribusiness, and financial services fields. Mr. Mills is currently serving as a consultant and advisor to Arianna S.A., a European specialized investment fund. He also serves on the boards of Black Hills Corporation (where he serves as Chair of the board), Farmers Edge, Inc., Illinois College (where he also serves as the Chair of the board), First Illinois Corporation (along with its wholly-owned banking subsidiary, Hickory Point Bank & Trust) and Arianna S.A. Mr. Mills holds a Bachelor of Science degree in Mathematics from Illinois College.   Key Qualifications   Mr. Mills’ familiarity with Amyris, as well as his expertise in accounting, finance, and management, enables him to assist our management team and Board build and improve our business, and financial and risk management processes.

 

AMYRIS, INC. 2022 PROXY STATEMENT    11

---

Table of Contents

Proposal 1 — Director Biographies  |  Class II Incumbent Directors with a Term Expiring in 2024

 

Class II Incumbent Directors with a Term Expiring in 2024

 

Director since 2017   Age 53   Board Committees None   Other Current Public Directorships None		Philip Eykerman   Mr. Eykerman has served as the Executive Vice-President, Corporate Strategy & Acquisitions of Koninklijke DSM N.V. (together with its affiliates, “DSM”), a global science-based company in nutrition, health and sustainable living and an entity with which Amyris has a commercial and financial relationship and which is an owner of greater than five percent of the Company’s outstanding common stock, since 2011. In this role, he has been responsible for corporate and business group strategy development, budgeting and planning, improvement programs, and all M&A activities. In 2015, he was also appointed as a member of the DSM Executive Committee. Since September 2020, he is also serving as the President Health Nutrition & Care, thereby managing and overseeing all the group’s activities in health, nutrition & care, while maintaining the responsibility for the DSM Mergers & Acquisitions activities. In addition to these roles within DSM, he is also a Supervisory Board member of ChemicaInvest (DSM/CVC JV) and AnQore TopCo B.V. Before joining DSM, Mr. Eykerman worked for 14 years at McKinsey & Company, the last 9 years of which he served as a Partner and leader of McKinsey’s Chemicals Practice in the Benelux and France. He holds a Master’s degree in Chemical Engineering from the KU Leuven (Belgium), and a Master’s degree in Refinery Engineering from the Institut Francais du Pétrole (France).   Key Qualifications   Mr. Eykerman’s experience in corporate strategy, mergers and acquisitions, and operations enables him to provide insight to the Board regarding potential new opportunities for Amyris.

 

Director since 2017   Age 73   Board Committees None   Other Current Public Directorships TOT Biopharm International Company Ltd. (HKG: 1875)		Frank Kung   Dr. Kung is a founding member of Vivo Capital LLC (“Vivo”), a healthcare focused investment firm founded in 1996 in Palo Alto, California. Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company in 1983. In 1983, he co-founded Genelabs Technologies, Inc. where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991, and built it to a 175-employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan. Dr. Kung currently serves on the boards of directors of a number of healthcare and biotechnology companies, including TOT Biopharm International Company Ltd. Dr. Kung holds a Bachelor of Science degree in chemistry from the National Tsing Hua University in Taiwan, and a PhD in molecular biology and an MBA from the University of California, Berkeley.   Key Qualifications   Dr. Kung’s experience in the healthcare and biotechnology industries, and with investing in companies, enables him to provide the Board and management with guidance regarding the Company’s business strategy and access to the financial markets.

 

12    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Proposal 1 — Director Biographies  |  Class II Incumbent Directors with a Term Expiring in 2024

 

Director since 2007   Age 56   Board Committees None   Other Current Public Directorships None		John Melo   Mr. Melo has nearly three decades of combined experience as an entrepreneur and thought leader in the global fuels industry and technology innovation. Mr. Melo has served as our CEO and a director since January 2007 and as our President since June 2008. Before joining Amyris, Mr. Melo served in various senior executive positions at BP Plc (formerly British Petroleum), one of the world’s largest energy firms, from 1997 to 2006, most recently as President of U.S. Fuels Operations. During his tenure at BP, Mr. Melo also served as Chief Information Officer of the refining and marketing segment, Senior Advisor for e-business strategy to Lord Browne, BP Chief Executive, and Director of Global Brand Development. Before joining BP, Mr. Melo was with Ernst & Young, an accounting firm, and served on the management teams of several startup companies, including Computer Aided Services, a management systems integration company, and Alldata Corporation, a provider of automobile repair software to the automotive service industry. Mr. Melo currently serves on the boards of Renmatix, Inc., the Industrial and Environmental section of the Biotechnology Innovation Organization, and the California Life Sciences Association. Mr. Melo was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum.   Key Qualifications   Mr. Melo’s experience as a senior executive at one of the world’s largest energy companies provides critical leadership in shaping strategic direction and business transactions, and in building teams to drive innovation, and as our CEO of over 15 years, he brings to our Board a deep and comprehensive knowledge of our business as well as shareholder-focused insight into effectively executing the Company’s strategy and business plans to maximize shareholder value.

 

Director since 2020   Age 56   Board Committees Leadership, Development, Inclusion & Compensation Committee   Other Current Public Directorships None		Julie Spencer Washington   Ms. Washington has served as Chief Marketing, Communications & Customer Experience Officer of Trinity Health, a Catholic health care delivery system, since January 2020. She previously served as Chief Marketing Officer of Champion Petfoods from 2017 to 2019 and held a number of executive positions at Jamba Juice from 2010 to 2016, including as Chief Marketing & Innovation Officer and prior to that, as Chief Brand Officer and Vice President and as General Manager, Consumer Products. Prior to that, Ms. Washington served in multiple senior leadership positions at Luxottica Retail, Procter & Gamble and Nestlé Purina. She currently serves on the board of directors of Union Institute & University. Ms. Washington holds a MBA from Washington University, a Bachelor of Arts degree in Chemistry and Psychology from Emory University, and an Executive in Education Certificate on Driving Digital and Social Strategy from Harvard University.   Key Qualifications   Ms. Washington’s experience in building and developing high-performing teams, fostering DEI efforts, leading business transformation, and driving sustainable corporate growth enables her to provide guidance to the Board and management on consumer needs and behaviors, market dynamics, and digital trends relevant to the Company’s business.

 

AMYRIS, INC. 2022 PROXY STATEMENT    13

---

Table of Contents

Proposal 1 — Election of Directors  |  Arrangements Concerning Selection of Directors

 

Arrangements Concerning Selection of Directors

In February 2012, pursuant to a Letter Agreement (the “Letter Agreement”) entered into in connection with the sale of our common stock to certain investors including Naxyris S.A. (“Naxyris”), an investment vehicle owned by Naxos Capital Partners S.C.A. (“Naxos”), we agreed to appoint, and to use reasonable efforts consistent with the Board’s fiduciary duties to cause the re-nomination by the Board in the future of one person designated by Naxyris to serve as a member of the Board. Pursuant to the Letter Agreement, Naxyris designated Carole Piwnica (who was already on the Board) to serve as the Naxyris representative on the Board. Ms. Piwnica stepped down from her position on the Board as of May 29, 2021, and we do not expect Naxyris to designate a new representative to our Board.

Pursuant to a Stockholder Agreement entered into in May 2017, and subsequently amended and restated in August 2017, in connection with the sale of our Series B 17.38% Convertible Preferred Stock and warrants to DSM (the “DSM Stockholder Agreement”), we agreed to appoint, and to use reasonable efforts consistent with the Board’s fiduciary duties to cause the re-nomination by the Board in the future of, two persons designated by DSM to serve as members of the Board. Pursuant to the DSM Stockholder Agreement, DSM initially designated Mr. Eykerman to serve as a DSM representative on the Board and, following the amendment and restatement of the DSM Stockholder Agreement in August 2017, DSM designated Christoph Goppelsroeder to serve as the second DSM representative on the Board. DSM’s designation rights terminate, with respect to one designee, at such time as DSM beneficially owns less than 10% of our outstanding common stock and, with respect to both designees, at such time as DSM beneficially owns less than 4.5% of our outstanding common stock. As of March 1, 2022, DSM beneficially owned 16,701,210 shares of our common stock, representing approximately 5.3% of our outstanding common stock. As a result, Mr. Goppelsroeder stepped down from his position on the Board as of April 1, 2021. Mr. Eykerman, who remains on the Board, is an employee of DSM and receives compensation and benefits from DSM pursuant to its standard compensation policies and practices.

In August 2017, pursuant to a Stockholder Agreement (the “Vivo Stockholder Agreement”) entered into in connection with the sale of our common stock, Series D Convertible Preferred Stock and warrants to Vivo Capital LLC (“Vivo”), we agreed to appoint, and to use reasonable efforts consistent with the Board’s fiduciary duties to cause the re-nomination by the Board in the future of, one person designated by Vivo to serve as a member of the Board. Pursuant to the Vivo Stockholder Agreement, Vivo designated Dr. Kung to serve as the Vivo representative on the Board. Vivo’s designation rights terminate at such time as Vivo beneficially owns less than 4.5% of our outstanding common stock. As of March 1, 2022, Vivo beneficially owned 11,642,195 shares of our common stock, representing approximately 3.7% of our outstanding common stock. Notwithstanding Vivo’s current stock ownership, Dr. Kung continues to serve on the Board and we expect him to continue to serve as a director until his resignation or until his successor is duly elected by the holders of our common stock. Dr. Kung is a founding member of Vivo and receives compensation and benefits from Vivo pursuant to its standard compensation policies and practices.

Mr. Doerr and Dr. Duyk were initially designated to serve on the Board by KPCB and TPG, respectively, pursuant to a voting agreement amended and restated on June 21, 2010. Dr. Duyk resigned from the Board in May 2011 and was re-appointed to the Board in May 2012. As of the date of this Proxy Statement, notwithstanding the expiration of the voting agreement upon completion of our initial public offering in September 2010, Mr. Doerr and Dr. Duyk continue to serve on the Board and we expect each of them to continue to serve as a director until his resignation or until his successor is duly elected by the holders of our common stock. Mr. Doerr receives compensation and benefits from KPCB pursuant to its standard compensation policies and practices, and Dr. Duyk retains a carried interest in certain funds managed by TPG.

Independence of Directors

Under the corporate governance rules of Nasdaq, a majority of the members of the Board must qualify as “independent,” as affirmatively determined by the Board. The Board and the NGC of the Board consult with our

 

14    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Proposal 1 — Election of Directors  |  Independence of Directors

 

legal counsel to ensure that the Board’s determinations are consistent with all relevant securities and other laws and regulations regarding the definition of “independent,” including those set forth in the applicable Nasdaq rules.

The Nasdaq criteria include various objective standards and a subjective test. A member of the Board is not considered independent under the objective standards if, for example, he or she is, or at any time during the past three years was, employed by Amyris, he or she received compensation (other than standard compensation for Board service) in excess of $120,000 during a period of twelve months within the past three years, or he or she is an executive officer of any organization to which Amyris made, or from which Amyris received, payments for property or services (other than payments arising solely from investments in our securities or payments under non-discretionary charitable contribution matching programs) in the current or any of the past three fiscal years that exceed 5% of the recipient’s gross revenues for that year, or $200,000, whichever is more.

The subjective test under the Nasdaq rules for director independence requires that each independent director not have a relationship which, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The subjective evaluation of director independence by the Board was made in the context of the objective standards referenced above. In making independence determinations, the Board generally considers commercial, financial and professional services, and other transactions and relationships between Amyris and each director and his or her family members and affiliated entities.

Based on such criteria, the Board determined that (i) Mr. Melo is not independent because he is an Amyris employee and (ii) Mr. Eykerman is not independent because he is an employee of DSM (with which we have commercial and financial relationships, as described below under “Transactions with Related Persons”).

For each of the directors other than Messrs. Melo and Eykerman, the Board determined that none of the transactions or other relationships of such directors (and their respective family members and affiliated entities) with Amyris, our executive officers, and our independent registered public accounting firm exceeded the Nasdaq objective standards and none would otherwise interfere with the exercise of independent judgment in carrying out his or her responsibilities as a director. The following is a description of these relationships:

 

◾

Mr. Doerr indirectly owns all of the membership interests in Foris Ventures, LLC (“Foris”) and Perrara Ventures, LLC, which beneficially owned 90,615,358 and 3,333,333 shares of our common stock, respectively, representing in the aggregate approximately 29.7% of our outstanding common stock as of March 1, 2022. Mr. Doerr is also a manager of the general partners of entities affiliated with KPCB Holdings, Inc (“KPCB”). As of March 1, 2022, KPCB Holdings, Inc., as nominee for entities affiliated with KPCB, held 278,882 shares of our common stock, which represented less than 1% of our outstanding common stock.

 

◾

Dr. Kung is a founding member of, and was designated to serve as a director by Vivo. As of March 1, 2022, Vivo beneficially owned 11,642,195 shares of our common stock, representing approximately 3.7% of our outstanding common stock. In addition, Dr. Kung’s daughter is a non-executive employee of Amyris.

 

◾

Mr. Panchadsaram is a partner at Foris, which beneficially owned 90,615,358 shares of our common stock, representing in the aggregate approximately 28.6% of our outstanding stock as of March 1, 2022. Mr. Panchadsaram also serves as an advisor to the Chairman of KPCB. As of March 1, 2022, KPCB, as nominee for entities affiliated with KPCB, held 278,882 shares of our common stock, which represented less than 1% of our outstanding common stock.

Consistent with these considerations, after a review of all relevant transactions and relationships between each director, any of his or her family members and affiliated entities, Amyris, our executive officers and our independent registered public accounting firm, the Board affirmatively determined that a majority of the Board is comprised of independent directors, and that the following directors are independent: John Doerr, Ana Dutra, Geoffrey Duyk, Frank Kung, James McCann, Steven Mills, Ryan Panchadsaram, Lisa Qi, and Julie Spencer Washington.

 

AMYRIS, INC. 2022 PROXY STATEMENT    15

---

Table of Contents

Proposal 1 — Election of Directors  |  Board Skills and Diversity

 

Board Tenure

 

 

Board Skills and Diversity

Board Skills, Experience and Attributes

 

 

 

16    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Proposal 1 — Election of Directors  |  Board Leadership Structure

 

		GENDER		ETHNIC DIVERSITY

 

 

The following Board Diversity Matrix presents our Board diversity statistics in accordance with Nasdaq Rule 5606, as self-disclosed by our directors, confirming compliance with the minimum objectives of such rule.

 

Board Diversity Matrix (As of March 31, 2022)
Total Number of Directors		11

		Female					Male					Non-Binary					Did not Disclose Gender
Directors				3					8					—					—
Number of Directors who identify in Any of the Categories Below:
African American or Black				1					—					—					—
Alaskan Native or Native American				—					—					—					—
Asian				1					2					—					—
Hispanic or Latinx				1					—					—					—
Native Hawaiian or Pacific Islander				—					—					—					—
White				—					5					—					—
Two or More Races or Ethnicities				—					—					—					—
LGBTQ+				—					—					—					—
Did not Disclose Demographic Background				—					1					—					—

Board Leadership Structure

The Board is composed of our CEO, John Melo, and ten non-management directors. Geoffrey Duyk, one of our independent directors, currently serves the principal Board leadership role as the interim Board Chair. The Board does not have any policy that the Board Chair must necessarily be separate from the CEO, but the Board appointed Dr. Duyk as interim Board Chair in May 2014 and he continues to serve in this role today. Dr. Duyk’s current responsibilities as interim Board Chair include working with the CEO to develop agendas for Board meetings, calling special meetings of the Board or Committees, presiding at executive sessions of independent Board members, and ensuring that an annual self- assessment process is conducted in order to provide feedback to the Board, its Committees and Committee Chairs, and the CEO, as appropriate, and serving as CEO in the absence of another designated CEO. The Board believes that having an independent Board Chair helps reinforce the Board’s independence from management in its oversight of our business and affairs.

 

AMYRIS, INC. 2022 PROXY STATEMENT    17

---

Table of Contents

Proposal 1 — Election of Directors  |  Board Committees and Meetings

 

In addition, the Board believes that this structure helps to create an environment that is conducive to objective evaluation and oversight of management’s performance and related compensation, increasing management accountability and improving the ability of the Board to monitor whether management’s actions are in our best interests and those of our stockholders. Further, this structure permits our CEO to focus on the management of our day-to-day operations. Accordingly, we believe our current Board leadership structure contributes to the effectiveness of the Board as a whole and, as a result, is the most appropriate structure for us at the present time.

Board Committees and Meetings

The Board has established an Audit Committee, a LDICC, and an NGC, each as described below. Members are appointed by the Board to serve on these Committees until their resignations or until otherwise determined by the Board. A copy of each Committee’s charter can be found on our website at https://investors.amyris.com/corporate-governance.

During 2021, the Board held four meetings, and its three standing Committees (the Audit Committee, LDICC and NGC) collectively held 24 meetings. Each incumbent director attended at least 75% of the meetings of the Board and of the Committees on which such director served that were held during the period that such director served in 2021. The Board’s policy is that directors are encouraged to attend our annual meetings of stockholders. No directors attended our 2021 annual meeting of stockholders.

In August 2021, the Board, at the NGC’s proposal, approved the dissolution of the Operations and Finance Committee (“OFC”). The OFC’s purpose was to review and approve strategic transactions presenting sensitive competition issues. However, upon review and discussion, the Board determined that the OFC was no longer needed and that the Board would continue reviewing and approving the Company’s significant M&A, financing, and strategic transactions. Before its dissolution, the OFC held three meetings during 2021.

The following table provides membership for the Board’s standing committees as of December 31, 2021:

 

		Independent Director		Audit Committee		Nominating & Governance Committee		Leadership,   Development,   Inclusion &   Compensation   Committee
John Doerr
Geoffrey Duyk M.D., Ph.D.
James McCann
Steve Mills
Ryan Panchadsaram
Lisa Qi
Julie Spencer Washington

 Chair      Member

 

18    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Proposal 1 — Election of Directors  |  Board Committees and Meetings

 

Outlined below are brief descriptions of the roles and responsibilities of each standing Committee.

 

		Audit Committee   Current members: Steve Mills (Chair) Geoffrey Duyk Ryan Panchadsaram   Others who served in 2021: James McCann (resigned from Committee in August 2021)   Number of meetings held in 2021: 8   The Board has determined that each member of the Audit Committee is independent (as defined in the relevant Nasdaq and Securities and Exchange Commission (“SEC”) rules and regulations), and is financially literate and able to read and understand fundamental financial statements, including a company’s balance sheet, income statement and cash flow statement.   In addition, the Board has determined that Mr. Mills is an “audit committee financial expert” as defined in Item 407(d)(5)(ii) of Regulation S-K promulgated under the Securities Act of 1933, as amended (the “Securities Act”), with employment experience in finance and accounting and other comparable experience that results in his financial sophistication.						Role and Responsibilities   The Audit Committee assists the Board in fulfilling the Board’s oversight of our accounting and system of internal controls, the quality and integrity of our financial reports, legal and regulatory matters, and the retention, independence and performance of our independent registered public accounting firm.   The Audit Committee performs, among others, the following functions:   ◾  oversees our accounting and financial reporting processes and audits of our consolidated financial statements and disclosure thereof;   ◾  oversees our relationship with our independent auditors, including appointing or changing our independent auditors and ensuring their independence;   ◾  monitors our risk assessment and management, and compliance with legal and regulatory requirements, including oversight of cybersecurity risks;   ◾  reviews and approves the audit and permissible non-audit services to be provided to us by our independent auditors;   ◾  facilitates communication among our independent auditors, our financial and senior management, and the Board;   ◾  monitors the periodic reviews of the adequacy of our accounting and financial reporting processes and systems of internal control that are conducted by our independent auditors and our financial and senior management; and   ◾  oversees management’s plans and objectives for Amyris’s capitalization and reviews and approves new offerings of debt, equity or hybrid securities, stock splits, and credit agreements, as well as minority investments by Amyris.   The Audit Committee also reviews and approves any proposed transaction between Amyris and any related party, establishes procedures for the receipt, retention and treatment of complaints received by Amyris regarding accounting, internal accounting controls or auditing matters, and together with the Secretary and Compliance Officer, for the confidential, anonymous submission by Amyris employees of their concerns regarding suspected violations of laws, governmental rules or regulations, accounting, internal accounting controls or auditing matters, or company policies (including the administration of our whistleblower policy), and in coordination with the Secretary, oversees the review of any complaints and submissions received through the complaint and anonymous reporting procedures.

 

		Nominating & Governance Committee   Current members: John Doerr (Chair) James McCann Lisa Qi   Number of meetings held in 2021: 4   The Board has determined that each member of the NGC is independent (as defined in the relevant Nasdaq and SEC rules and regulations).						Role and Responsibilities   The NGC ensures that the Board is properly constituted to meet its fiduciary obligations to stockholders and Amyris, and to assist the Board with respect to corporate governance matters, including:   ◾  identifying, considering and nominating candidates for membership on the Board;   ◾  overseeing and recommending corporate governance guidelines and policies for Amyris (including our Corporate Governance Principles, Code of Business Conduct and Ethics and Insider Trading Policy);   ◾  Overseeing the development and achievement of ESG objectives by management;   ◾  overseeing the evaluation of the Board and its committees; and   ◾  advising the Board on corporate governance and Board performance matters, including recommendations regarding the structure and composition of the Board and Board Committees.   The NGC also monitors the size, structure and composition of the Board and its Committees and makes any recommendations to the Board regarding improvements to each Committee’s operations (including Committee reports to the Board), and structure (including member qualifications, appointment and removal), reviews our narrative disclosures in SEC filings regarding the director nomination process, director qualifications, Board leadership structure and risk oversight by the Board, considers and approves requested waivers for our directors or executive officers under our Code of Business Conduct and Ethics, reviews and makes recommendations to the Board regarding formal procedures for stockholder communications with members of the Board, and oversees an annual self-assessment process for the Board, its Committees and the Directors.

 

AMYRIS, INC. 2022 PROXY STATEMENT    19

---

Table of Contents

Proposal 1 — Election of Directors  |  Board Committees and Meetings

 

		Leadership, Development, Inclusion & Compensation Committee   Current members: James McCann (Chair) Steve Mills Ryan Panchadsaram Julie Spencer Washington   Number of meetings held in 2021: 8   The Board, after consideration of all factors specifically relevant to determining whether any of Mr. McCann, Mr. Mills, Mr. Panchadsaram, or Ms. Washington has a relationship to Amyris that is material to that director’s ability to be independent from management in connection with the duties of a LDICC member, including, but not limited to, (i) the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by Amyris to such director and (ii) whether such director is affiliated with Amyris, has determined that each member of the LDICC is independent (as further defined in the relevant Nasdaq and SEC rules and regulations).						Role and Responsibilities   The purpose of the LDICC is to provide guidance and periodic monitoring for all of our compensation, benefits and equity programs. The LDICC, through delegation from the Board, has principal responsibility to evaluate, recommend, approve, and review executive officer and director compensation arrangements, plans, policies and programs maintained by Amyris and to administer our equity-based and cash-based compensation plans, and may also make recommendations to the Board relating to executive compensation. The LDICC discharges the responsibilities of the Board relating to compensation of our executive officers, and, among other things:   ◾  reviews and approves the compensation of our executive officers;   ◾  reviews and recommends to the Board the compensation of our non-employee directors;   ◾  reviews and recommends to the Board the terms of material amendments to equity compensation agreements in which our executive officers may participate;   ◾  reviews and approves the terms of cash-based compensation agreements with our executive officers;   ◾  administers our stock and equity incentive plans;   ◾  reviews and makes recommendations to the Board with respect to incentive compensation and equity incentive plans other than as described above;   ◾  establishes and reviews our overall compensation strategy;   ◾  reviews with our CEO and Board leadership the succession plans for the executive officers; and   ◾  oversees human capital management and DEI strategies and practices.

 

20    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Proposal 1 — Election of Directors  |  Board and Committee Oversight of Risk Management

 

Board and Committee Oversight of Risk Management

 

Full Board   The Board as a whole oversees our risk management systems and processes. Each of the standing Committees has been delegated oversight of certain categories of risk and provides the Board with regular reports regarding the Committees’ activities.   Assessing and managing risk is the responsibility of our management, which establishes and maintains risk management processes, including prioritization, action plans and mitigation measures, designed to balance the risk and benefit of opportunities and strategies. It is management’s responsibility to anticipate, identify and communicate risks to the Board and/or its Committees and discuss strategic plans and objectives, business results, financial condition, compensation programs, strategic transactions, and other matters in the context of various categories of risk.

Audit Committee   Responsible for overseeing our financial controls and risk, litigation and regulatory matters, and certain legal compliance matters, as well as enterprise risk prioritization and mitigation (including cybersecurity risk), and management’s plans and objectives for our capitalization

Nominating & Governance Committee   Responsible for overseeing risks related to Board and Committee composition and succession, certain legal compliance matters, and corporate governance policies and practices (including ESG goals)

Leadership, Development, Inclusion & Compensation Committee   Responsible for overseeing risks associated with our Board, executive and employee compensation programs and related plans, effective management of executive succession, and management’s plans, policies and practices related to human capital (including DEI strategies)

Director Nomination Process

In carrying out its duties to consider and nominate candidates for membership on the Board, the NGC considers a mix of perspectives, qualities and skills that would contribute to the overall corporate goals and objectives of Amyris and to the effectiveness of the Board. The NGC’s goal is to nominate directors who will provide a balance of industry, business and technical knowledge, experience and capability. To this end, the NGC considers a variety of characteristics for director candidates, including demonstrated ability to exercise sound business judgment, relevant industry or business experience, understanding of, and experience with, issues and requirements facing public companies, excellence and a record of professional achievement in the candidate’s field, relevant technical knowledge or aptitude, having sufficient time and energy to devote to the affairs of Amyris, independence for purposes of compliance with Nasdaq and SEC rules and regulations, as applicable, and commitment to rigorously represent the long-term interests of our stockholders. Although the NGC uses these and other criteria to evaluate potential nominees, we have no stated minimum criteria for nominees. While we do not have a formal policy with regard to the consideration of diversity in identifying director nominees, the NGC strives to reflect current legal developments and modifications to public company standards regarding diversity and inclusion on public company boards, and to nominate directors with a variety of complementary skills and experience. Accordingly, the NGC endeavors for the Board, as a group, to possess the appropriate talent, skills and experience to oversee our business. With respect to four of the most recent additions to our Board membership, the Board considered diversity in its elections of Ms. Dutra, Mr. Panchadsaram, Ms. Qi, and Ms. Washington, and the value of adding additional gender and ethnic diversity to our Board, in addition to their specific professional areas of professional expertise and other qualifications.

 

AMYRIS, INC. 2022 PROXY STATEMENT    21

---

Table of Contents

Proposal 1 — Election of Directors  |  Board and Committee Oversight of Risk Management

 

The NGC generally uses the following processes for identifying and evaluating nominees for director:

 

◾

In the case of incumbent directors, the NGC reviews the directors’ overall service to Amyris during each annual assessment process, including performance, effectiveness, participation, and independence.

 

◾

In seeking to identify new director candidates, the NGC may use its network of contacts, together with the network of contacts of our CEO and Secretary, to compile a list of potential candidates and may also engage, if deemed appropriate, a professional search firm. The NGC would conduct any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the structure and needs of the Board. Our CEO and Secretary regularly review potential candidates with the NGC in order to discuss and consider such candidates’ qualifications prior to organizing meetings with select nominees which may lead to recommendations to the Board of such candidates’ membership by majority vote.

Stockholder Nominations

The NGC will consider director candidates recommended by stockholders and will use the same criteria to evaluate all candidates. We have not received a recommendation for a director nominee for the 2022 Annual Meeting from any stockholder. Stockholders who wish to recommend individuals for consideration by the NGC to become nominees for election to the Board may do so by delivering a written recommendation to the NGC at the following address: NGC Chair c/o Secretary of Amyris, Inc. at 5885 Hollis Street, Suite 100, Emeryville, California 94608, not later than the close of business on the 75^th day, nor earlier than the close of business on the 105^th day, prior to the anniversary date of the preceding year’s annual meeting of stockholders, which for our 2023 annual meeting of stockholders is not later than March 13, 2023 nor earlier than February 11, 2023. You are also advised to review our Bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations. Submissions must include the full name of the proposed nominee, a description of the proposed nominee’s business experience and directorships for at least the previous five years, complete biographical information, a description of the proposed nominee’s qualifications as a director and a representation that the nominating stockholder is a beneficial or record owner of our common stock. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected.

As provided in our Certificate of Incorporation, subject to the rights of the holders of any series of preferred stock, any vacancy occurring in the Board can generally be filled only by the affirmative vote of a majority of the directors then in office. The director appointed to fill the vacancy will hold office for a term expiring at the annual meeting of stockholders at which the term of office of the class to which the director has been assigned expires and until such director’s successor shall have been duly elected and qualified, or until such director’s earlier death, resignation or removal.

Stockholder Communications with Directors

The Board has established a process by which stockholders may communicate with the Board or any of its members, including the Board Chair, or to the independent directors generally. Stockholders and other interested parties who wish to communicate with the Board or any of the directors may do so by sending written communications addressed to the Secretary of Amyris at 5885 Hollis Street, Suite 100, Emeryville, California 94608. The Board has directed that the Secretary will review all communications to determine whether they should be presented to the Board. Following such review, the Secretary will determine which communications will be compiled and submitted to the Board, or a selected group of directors or individual directors, on a periodic basis. The purpose of this screening is to allow the Board to avoid having to consider irrelevant or inappropriate communications (such as advertisements and solicitations). The screening procedure has been approved by a majority of the non-management directors of the Board. Directors may at any time request that the Secretary forward to them immediately all communications received for the Board. All communications directed to the Audit Committee in accordance with the procedures described above that relate to accounting, internal accounting controls or auditing matters involving Amyris will be promptly and directly forwarded to the Chair of the Audit Committee who will direct distribution to the Audit Committee members as required.

 

22    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

		Proposal 2

 

Ratification of Appointment of Independent Registered Public Accounting Firm

General

The Audit Committee appointed Macias Gini & O’Connell LLP (“MGO”) as our independent registered public accounting firm for the fiscal year ending December 31, 2022, and the Board has directed that management submit the appointment of such independent registered public accounting firm for ratification by our stockholders at the Annual Meeting. MGO has been engaged as our independent registered public accounting firm since July 2019. We expect representatives of MGO to be present at the Annual Meeting. They will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.

Neither our Bylaws nor other governing documents or applicable law require stockholder ratification of the appointment of our independent registered public accounting firm. However, we are submitting the appointment of MGO to our stockholders for ratification as a matter of good corporate practice. If our stockholders fail to ratify the appointment, the Audit Committee will reconsider whether or not to retain MGO. Even if the appointment is ratified, the Audit Committee in its discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if they determine that such a change would be in the best interests of Amyris and our stockholders.

During our two most recent fiscal years, which ended December 31, 2021 and 2020, neither we nor any person on our behalf consulted with MGO with respect to either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our consolidated financial statements, and neither a written report was provided to us nor oral advice was provided that MGO concluded was an important factor in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a “disagreement” or a “reportable event,” as such terms are described in Items 304(a)(1)(iv) and 304(a)(1)(v) of Regulation S-K.

Vote Required and Board Recommendation

Ratification of the appointment of MGO requires the affirmative vote of the holders of a majority of the shares of common stock properly casting votes for or against this proposal at the Annual Meeting in person or by proxy. Abstentions will not count toward the vote total for this proposal and therefore will not affect the outcome of this proposal. Shares represented by executed proxies that do not indicate a vote “For,” “Against” or “Abstain” will be voted by the proxy holders “For” this proposal.

 

		The Board recommends a vote “FOR” this Proposal 2

 

AMYRIS, INC. 2022 PROXY STATEMENT    23

---

Table of Contents

Proposal 2   |  Ratification of Appointment of Independent Registered Public Accounting Firm

 

Independent Registered Public Accounting Firm Fee Information

MGO has served as our independent registered public accounting firm for the fiscal years ended December 31, 2021 and 2020. The following tables set forth the aggregate fees billed to us by MGO for services performed in or for those fiscal years then ended (in thousands):

 

		Fiscal Year ended December 31,
Fee Category		2021				2020
Audit Fees		$	1,763.4			$	2,084.8
Audit-Related Fees			—				—
Tax Fees			—				—
All Other Fees			124.3				91.8
Total Fees		$	1,887.7			$	2,176.6

The “Audit Fees” category includes aggregate fees billed for the relevant fiscal year for professional services rendered for the audit of our annual financial statements and review of our unaudited financial statements included in our Quarterly Reports on Form 10-Q, and for services that are normally provided in connection with statutory and regulatory filings or engagements for those fiscal years.

The “Audit-Related Fees” category includes aggregate fees billed in the relevant fiscal years for assurance and related services that are reasonably related to the performance of the audit or review of our consolidated financial statements and that are not reported under the “Audit Fees” category. We did not incur any fees in this category with respect to MGO for the fiscal years ended December 31, 2021 and 2020.

The “Tax Fees” category includes aggregate fees billed in the relevant fiscal year for professional services rendered with respect to tax compliance, tax advice and tax planning. We did not incur any fees in this category with respect to MGO for the fiscal years ended December 31, 2021 and 2020.

The “All Other Fees” category includes aggregate fees billed in the relevant fiscal year for products and services other than those reported under the other categories described above. In the fiscal years ended December 31, 2021 and 2020, we incurred fees in this category related to our private placement transaction and the filing of registration statements on Forms S-1, S-3ASR and S-8.

Audit Committee Pre-Approval of Services Performed by our Independent Registered Public Accounting Firm

The Audit Committee’s charter requires it to approve all fees and other compensation paid to, and pre-approve all audit and non-audit related services provided by, the Company’s independent registered public accounting firm. The Audit Committee charter permits the Audit Committee to delegate pre-approval authority to one or more members of the Audit Committee, provided that any pre-approval decision is reported to the Audit Committee at its next scheduled meeting. The Audit Committee has delegated such pre-approval authority, for fees of up to $100,000 in the aggregate, to the Chair of the Audit Committee.

In determining whether to approve audit and non-audit services to be performed by our independent registered public accounting firm, the Audit Committee takes into consideration the fees to be paid for such services and whether such fees would affect the independence of the accounting firm in performing its audit function. In addition, when determining whether to approve non-audit services to be performed by our independent registered public accounting firm, the Audit Committee considers whether the performance of such services is compatible

 

24    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Proposal 2   |  Ratification of Appointment of Independent Registered Public Accounting Firm

 

with maintaining the independence of the accounting firm in performing its audit function, and confirms that the non-audit services will not include the prohibited activities set forth in Section 201 of the Sarbanes-Oxley Act of 2002. Except for the services described above under “Audit-Related Fees,” “Tax Fees,” and “All Other Fees” (each of which was pre-approved by the Audit Committee in accordance with its policy), no non-audit services were provided by our independent registered public accounting firm in 2021 or 2020.

All fees paid to, and all services provided by, our independent registered public accounting firm during fiscal years 2021 and 2020 were pre-approved by the Audit Committee in accordance with the pre-approval procedures described above.

Report of the Audit Committee*

The Audit Committee has reviewed and discussed with management our audited consolidated financial statements for the fiscal year ended December 31, 2021. The Audit Committee has also discussed with MGO, our independent registered public accounting firm, the matters required to be discussed by Public Company Accounting Oversight Board Auditing Standard No. 1301 (Communications with Audit Committees), as amended.

The Audit Committee has received and reviewed the written disclosures and the letter from MGO required by applicable requirements of the Public Company Accounting Oversight Board regarding MGO’s communications with the Audit Committee concerning independence, and has discussed with MGO its independence.

Based on the review and discussions referred to above, the Audit Committee recommended to the Board that the audited consolidated financial statements be included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 for filing with the SEC.

Amyris, Inc. Audit Committee of the Board

Steven Mills (Chair)

Geoffrey Duyk

Ryan Panchadsaram

 

*

The material in this report is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference into any filing of Amyris under the Securities Act or the Securities Exchange Act of 1934 (the “Exchange Act”), whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

 

AMYRIS, INC. 2022 PROXY STATEMENT    25

---

Table of Contents

		Proposal 3

 

Approval of Amendment of Restated Certificate of Incorporation to increase the Total Number of Authorized Shares of Common Stock

General

We are asking stockholders to approve an amendment (the “Amendment”) to Article IV of our restated Certificate of Incorporation to increase the total number of our authorized shares from 455,000,000 to 555,000,000 and the number of authorized shares of common stock from 450,000,000 to 550,000,000 (the “Authorized Share Increase”). The Board has approved the advisability of, and has adopted, subject to stockholder approval, the Amendment and the Authorized Share Increase. The Amendment requires approval of both the Board and our stockholders. Accordingly, we are seeking stockholder approval for the Amendment at the Annual Meeting by means of this Proxy Statement. The form of the proposed Amendment is attached to this Proxy Statement as Appendix A and is incorporated herein by reference.

Article IV of our Certificate of Incorporation currently authorizes us to issue up to 455,000,000 shares of stock, with 450,000,000 designated as common stock and 5,000,000 designated as preferred stock. The additional common stock will have rights identical to our currently outstanding common stock. The number of authorized shares of our preferred stock will not be affected by this amendment; it will be maintained at 5,000,000 shares. No other changes are being proposed to our Certificate of Incorporation.

Our common stock consists of a single class, with equal voting, distribution, liquidation and other rights. As of March 30, 2022, of our 450,000,000 shares of authorized common stock, 317,975,269 shares were issued and outstanding and approximately 140 million shares were reserved for issuance under our current equity plans, outstanding convertible promissory notes, outstanding convertible preferred stock, and other outstanding rights to acquire common stock.

Purpose of the Authorized Share Increase

The reason for the proposed amendment is to increase our financial flexibility to pursue strategic opportunities from time to time, including potential acquisitions and other capital-intensive opportunities, and to facilitate our ability to continue implementing our employee equity programs at competitive levels. Our cash flow from operations has been, and continues to be, negative. We may need to raise additional operating capital. The Board may determine that the optimal manner for doing so is the sale of equity securities, instruments convertible into equity securities or options or rights to acquire equity securities. For example, since 2013 we have been engaging in financings involving the private placement of our common stock, convertible promissory notes or warrants.

The increase in authorized shares of common stock will give the Board the flexibility to undertake certain transactions to support our business operations, without the potential expense or delay associated with obtaining stockholder approval for any particular issuance. We do not currently have enough shares authorized to provide sufficient flexibility to pursue appropriate financing opportunities if they arise, or to take certain other actions that the Board may determine are in our best interests and the best interests of our stockholders. For example, we

 

26    AMYRIS, INC. 2021 PROXY STATEMENT

---

Table of Contents

Proposal 3   |  Approval of Amendment of Restated Certificate of Incorporation to increase the Total Number of Authorized Shares of Common Stock

 

could issue additional shares of common stock in the future in connection with one or more of the following (subject to laws, regulations or Nasdaq rules that might require stockholder approval of certain transactions):

 

◾

strategic investments;

 

◾

acquisitions;

 

◾

partnerships, collaborations and other similar transactions;

 

◾

financing transactions, such as public or private offerings of common stock or convertible securities;

 

◾

debt or equity restructuring or refinancing transactions;

 

◾

stock splits or stock dividends; or

 

◾

any other proper corporate purposes.

The increase will also facilitate our ability to continue implementing our employee equity programs at competitive levels. As of March 30, 2022, all of our currently authorized shares of common stock has either been issued or reserved for issuance under our equity incentive plans or upon exercise of outstanding warrants or conversion of outstanding convertible promissory notes, or needs to be reserved for issuance upon exercise of outstanding rights (as described below), after taking into consideration the full potential of interest that accrues and can convert to, or be payable in, shares of our common stock (including the shares of common stock to be issued subject to approval of Proposal 3).

Vote Required and Board Recommendation

This proposal must receive a “For” vote from the holders of a majority of our outstanding shares of common stock entitled to vote at the Annual Meeting, irrespective of the number of votes cast on the proposal at the meeting. If you own shares through a bank, broker or other Intermediary, you must instruct your bank, broker or other Intermediary how to vote in order for them to vote your shares so that your vote can be counted on this proposal. Abstentions and broker non-votes will have the same effect as an “Against” vote for this proposal.

 

		The Board recommends a vote “FOR” this Proposal 3.

The Board believes it is desirable for us to have the flexibility to issue, without further stockholder action, additional shares of common stock in excess of the amount that is currently authorized. As is the case with the current authorized, unreserved, and unissued shares of common stock, the additional shares of common stock authorized by this proposed amendment could be issued upon approval by the Board or the LDICC, as applicable, without further vote of our stockholders except as may be required in particular cases by applicable law, regulatory agencies or Nasdaq rules. Such shares would be available for issuance from time to time as determined by the Board or the LDICC, as applicable, for any proper corporate purpose. Such purposes might include, without limitation, issuance in public or private sales for cash as a means of obtaining additional capital for use in our business and operations, issuance in repayment of indebtedness and/or issuance pursuant to stock plans relating to options, restricted stock, restricted stock units and other equity grants.

Potential Adverse Effects

If this proposal is adopted, the additional authorized shares of common stock can be issued or reserved with approval of the Board or the LDICC, as applicable, at times, in amounts, and upon terms that the Board, or the LDICC, may determine, without additional stockholder approval. Stockholder approval of this proposal will not, by

 

AMYRIS, INC. 2022 PROXY STATEMENT    27

---

Table of Contents

Proposal 3   |  Approval of Amendment of Restated Certificate of Incorporation to increase the Total Number of Authorized Shares of Common Stock

 

itself, cause any change in our capital accounts. However, any future issuance of additional shares of authorized common stock, or securities convertible into common stock, would ultimately result in dilution of existing stockholders who do not participate in such transactions, and could also have a dilutive effect on book value per share and any future earnings per share. Dilution of equity interests could also cause prevailing market prices for our common stock to decline. Current stockholders (other than those who are party to specific rights agreements with us, as described below) will not have preemptive rights to purchase additional shares.

In addition to dilution, the availability of additional shares of common stock for issuance could, under certain circumstances, discourage or make more difficult any efforts to obtain control of Amyris. For example, significant stock and convertible security issuances in connection with a series of private-placement financing and public equity capital raise efforts since 2012 have resulted in further concentration of ownership of Amyris by related parties. Such concentration of ownership could make it more difficult for an unrelated third party to undertake an acquisition of us. The Board is not aware of any actual or contemplated attempt to acquire control of Amyris and this proposal is not being presented with the intent that it be used to prevent or discourage any acquisition attempt. However, nothing would prevent the Board from taking any actions that it deems consistent with its fiduciary duties.

Risks to Stockholders of Non-Approval

Because our cash flow from operations has been negative, if the stockholders do not approve this proposal, the Board may be precluded from pursuing a wide range of potential corporate opportunities that might raise necessary cash or otherwise be in the best interests of Amyris and the best interests of our stockholders, or from fulfilling certain equity obligations under our equity plans. This could have a material adverse effect on our business and prospects. We would also face substantial challenges in hiring and retaining employees at all levels, including our Executive Leadership Team, in the near term.

Interests of Certain Persons

Our executive officers and directors have an interest in this proposal by virtue of their being eligible to receive equity awards under our 2020 EIP, and any future equity incentive plan we adopt.

Some of our directors are affiliated with, or were appointed as directors by, entities that own convertible securities, rights and/or warrants that are convertible into or exercisable for shares of our common stock. Further, some of our directors are affiliated with, or were appointed as directors by, entities that may participate in future equity financings that will require issuance or reservation of shares authorized by the proposed amendment to our Certificate of Incorporation. The beneficial ownership of our directors and its affiliates is set forth in section “Security Ownership of Certain Beneficial Owners and Management” of this Proxy Statement.

DSM International B.V. and Vivo Capital LLC, each of which has or recently had relationships to our directors, all hold a right of first investment that allows them to participate in specified future securities offerings (pro rata based on their percentage ownership of then-outstanding common stock).

Text of Proposed Amendment

The text of the proposed amendment to our Certificate of Incorporation to effect the Authorized Share Increase is attached to this Proxy Statement as Appendix A. However, such text is subject to amendment to include such changes as may be required by the office of the Secretary of State of the State of Delaware or as the Board of Directors deems necessary and advisable to effect the Authorized Share Increase under this proposal.

 

28    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

		Security Ownership of Certain Beneficial Owners and Management

 

The following table sets forth information with respect to the beneficial ownership of our common stock, as of March 1, 2022, by:

 

◾

each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our voting securities;

 

◾

each of our directors;

 

◾

each of our named executive officers; and

 

◾

all of our directors and executive officers as a group.

Beneficial ownership is determined in accordance with the rules of the SEC and generally includes any shares over which the individual or entity has sole or shared voting power or investment power. These rules also treat as outstanding all shares of capital stock that a person would receive upon the exercise of any option, warrant or right or through the conversion of a security held by that person that are immediately exercisable or convertible or exercisable or convertible within 60 days of the date as of which beneficial ownership is determined. These shares are deemed to be outstanding and beneficially owned by the person holding those options, warrants or rights or convertible securities for the purpose of computing the number of shares beneficially owned and the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. The information does not necessarily indicate beneficial ownership for any other purpose. Except as indicated in the footnotes to the below table and pursuant to applicable community property laws, to our knowledge the persons named in the table below have sole voting and investment power with respect to all shares of common stock attributed to them in the table.

Information with respect to beneficial ownership has been furnished to us by each director and named executive officer and certain stockholders, and derived from publicly-available SEC beneficial ownership reports on Forms 3 and 4 and Schedules 13D and 13G filed by covered beneficial owners of our common stock. Percentage ownership of our common stock in the table is based on 316,635,256 shares of our common stock outstanding on March 1, 2022 (as reflected in the records of our stock transfer agent). Except as otherwise set forth below, the address of the beneficial owner is c/o Amyris, Inc., 5885 Hollis Street, Suite 100, Emeryville, California 94608.

 

AMYRIS, INC. 2022 PROXY STATEMENT    29

---

Table of Contents

Security Ownership of Certain Beneficial Owners and Management

 

Name and Address of Beneficial Owner		Number of Shares Beneficially Owned (#)				Percent of Class (%)
Foris Ventures, LLC(1)			90,615,358				28.6
BlackRock Inc.(2)			21,091,779				6.7
The Vanguard Group(3)			17,315,246				5.5
DSM International B.V.(4)			16,701,210				5.3
Farallon Entities(5)			16,690,427				5.3
Directors and Named Executive Officers:
John Melo(6)			504,170				*
John Doerr(1)(7)			94,262,350				29.7
Ana Dutra			—				—
Geoffrey Duyk(8)			14,034				*
Philip Eykerman(4)(9)			25,062				*
Frank Kung(10)			11,655,593				3.7
James McCann(11)			15,564				*
Steven Mills(12)			30,732				*
Ryan Panchadsaram(13)			2,690				*
Lisa Qi(14)			9,281				*
Julie Spencer Washington(15)			8,104				*
Eduardo Alvarez(16)			300,415				*
Nicole Kelsey(17)			153,625				*
Han Kieftenbeld(18)			82,366				*
All Directors and Executive Officers as a Group (14 Persons)(19)			107,063,986				33.8

*	Less than 1%.

(1)

Includes 16,680,334 shares of common stock issuable upon conversion of certain senior convertible notes issued to Foris under the Amended and Restated Loan and Security Agreement, dated June 1, 2022, as amended. Foris is indirectly owned by director John Doerr, who shares voting and investment control over the shares held by Foris. The address for Foris is 751 Laurel Street #717, San Carlos, California 94070.

(2)

According to the Schedule 13G filed with the SEC on February 4, 2022, BlackRock, Inc. (“Blackrock”) had shared voting power over 164,814 shares, sole dispositive power over 16,997,520 shares, and shared dispositive power over 317,726 shares. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of those shares and no one person’s interest in such shares is more than five percent of the total outstanding common shares. The address for BlackRock is 55 East 52nd Street, New York, New York 10055.

(3)

According to the Schedule 13G filed with the SEC on February 9, 2022, The Vanguard Group (“Vanguard”) had sole voting power over 20,794,896 shares and sole dispositive power over 21,091,779 shares. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of those shares and no one person’s interest in such shares is more than five percent of the total outstanding common shares. The address for Vanguard is 100 Vanguard Blvd., Malvern, Pennsylvania 19355.

(4)

DSM International B.V. is a wholly owned subsidiary of Koninklijke DSM N.V. Accordingly, Koninklijke DSM N.V. may be deemed to share beneficial ownership of the securities held of record by DSM International B.V. Koninklijke DSM N.V. is a publicly traded company with securities listed on the Amsterdam Stock Exchange. The address for DSM International B.V. is HET Overloon 1, 6411 TE Heerlen, Netherlands.

(5)

According to the Schedule 13G/A filed with the SEC on February 23, 2022, Farallon Partners, L.L.C. (“Farallon General Partner”), on its own behalf and as the general partner of Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Farallon Capital Offshore Investors II, L.P., and Farallon Capital (AM) Investors, L.P., had shared voting and dispositive power over 15,906,515 shares held directly held by such Farallon entities. Farallon Institutional GP V, L.L.C. (“FCIP V General Partner”), as general partner of Four Crossings Institutional Partners V, L.P., had shared voting and dispositive power over 414,510 shares. Farallon F5 (GP), L.L.C. (“F5MI General Partner”), as general partner of Farallon Capital F5 Master I, L.P., had shared voting and dispositive power over 783,912 shares. Farallon Healthcare Partners (GP), L.L.C. (“FHPM General Partner”), as general partner of Farallon Healthcare Partners Master, L.P., had shared voting and dispositive power over 6,898,130 shares.

 

30    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Security Ownership of Certain Beneficial Owners and Management

 

As managing member or senior managing member of Farallon General Partner and manager or senior manager of FCIP V General Partner, F5MI General Partner and FHPM General Partner, Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, Andrew J. M. Spokes, John R. Warren and Mark C. Wehrly each had shared voting and dispositive power over the shares held by the Farallon Entities. The address for Farallon Entities is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, California 94111.

(6)	Shares beneficially owned by Mr. Melo include 130,893 shares of common stock issuable upon exercise of stock options that were exercisable within 60 days of March 1, 2022.

(7)

Shares beneficially owned by Mr. Doerr include (i) 90,615,358 shares of common stock beneficially owned by Foris, in which Mr. Doerr indirectly owns all of the membership interests, (ii) 3,333,333 shares of common stock beneficially owned by Perrara Ventures, LLC, in which Mr. Doerr indirectly owns all of the membership interests, (iii) 567 shares of common stock held by The Vallejo Ventures Trust U/T/A 2/12/96, of which Mr. Doerr is a trustee, (iv) 278,882 shares of common stock held by entities affiliated with Kleiner Perkins Caufield & Byers of which Mr. Doerr is an affiliate, excluding 16,399 shares over which Mr. Doerr has no voting or investment power and (v) 15,464 shares of common stock issuable upon exercise of stock options that were exercisable within 60 days of March 1, 2022.

(8)	Shares beneficially owned by Dr. Duyk include 2,436 restricted stock units vesting within 60 days of March 1, 2022 and 11,598 shares of common stock issuable upon exercise of stock options that were exercisable within 60 days of March 1, 2022.

(9)

Shares beneficially owned by Mr. Eykerman include 15,131 shares of common stock issuable upon exercise of stock options that were exercisable within 60 days of March 1, 2022. Mr. Eykerman was appointed to the Board on May 18, 2017 as the designee of DSM. Mr. Eykerman disclaims beneficial ownership of all shares of Amyris common stock that are or may be beneficially owned by DSM or any of its affiliates.

(10)

Shares beneficially owned by Dr. Kung include (i) 11,642,195 shares of common stock beneficially owned by Vivo Capital LLC (together with its affiliates, “Vivo”), over which Dr. Kung may be deemed to share voting and dispositive power and (ii) 13,398 shares of common stock issuable upon exercise of stock options that were exercisable within 60 days of March 1, 2022. Dr. Kung was appointed to the Board on November 2, 2017 as the designee of Vivo. Dr. Kung disclaims beneficial ownership over shares of Amyris common stock that are or may be beneficially owned by Vivo except to the extent of his pecuniary interest therein.

(11)	Shares beneficially owned by Mr. McCann include 2,860 restricted stock units vesting within 60 days of March 1, 2022 and 7,682 shares of common stock issuable upon exercise of stock options that were exercisable within 60 days of March 1, 2022.

(12)	Shares beneficially owned by Mr. Mills include 3,220 restricted stock units vesting within 60 days of March 1, 2022 and 10,398 shares of common stock issuable upon exercise of stock options that were exercisable within 60 days of March 1, 2022.

(13)	Shares beneficially owned by Mr. Panchadsaram include 2,690 restricted stock units vesting within 60 days of March 1, 2022.

(14)	Shares beneficially owned by Ms. Qi include 2,309 restricted stock units vesting within 60 days of March 1, 2022 and 4,216 shares of common stock issuable upon exercise of stock options that were exercisable within 60 days of March 1, 2022.

(15)	Shares beneficially owned by Ms. Washington include 2,372 restricted stock units vesting within 60 days of March 1, 2022 and 3,466 shares of common stock issuable upon exercise of stock options that were exercisable within 60 days of March 1, 2022.

(16)	Shares beneficially owned by Mr. Alvarez include 49,791 shares of common stock issuable upon exercise of stock options that were exercisable within 60 days of March 1, 2022.

(17)	Shares beneficially owned by Ms. Kelsey include 67,853 shares of common stock issuable upon exercise of stock options that were exercisable within 60 days of March 1, 2022.

(18)	Shares beneficially owned by Mr. Kieftenbeld include 34,556 shares of common stock issuable upon exercise of stock options that were exercisable within 60 days of March 1, 2022.

(19)	Shares beneficially owned by all of our executive officers and directors as a group include the shares of common stock described in footnotes 6 through 18 above.

 

AMYRIS, INC. 2022 PROXY STATEMENT    31

---

Table of Contents

		Executive Officers

 

The following table provides the names, ages, and offices of each of our current executive officers as of March 1, 2022:

 

Name		Age		Position
John Melo		56		Director, President and Chief Executive Officer
Han Kieftenbeld		56		Chief Financial Officer and Chief Administration Officer
Eduardo Alvarez		58		Chief Operating Officer
Nicole Kelsey		55		Chief Legal Officer and Secretary

John Melo

See above under “Proposal 1—Director Biographies”

Han Kieftenbeld

Han Kieftenbeld has served as our Chief Financial Officer since March 2020 and our Chief Administration Officer since July 2020. Mr. Kieftenbeld has over 30 years of international business leadership, finance and operations experience in food, health and nutrition end-markets. Previously, from April 2016 to April 2019, Mr. Kieftenbeld served as Senior Vice President and Chief Financial Officer of Innophos Holdings, Inc., a leading international science-based producer of essential ingredients for health and nutrition, food and beverage and industrial brands. From June 2014 to July 2015, Mr. Kieftenbeld served as the Global Chief Financial Officer at AB Mauri, a worldwide leader in bakery ingredients. Prior to that, Mr. Kieftenbeld held finance and operations roles of increasing reach and impact, including serving as Global Chief Procurement Officer of Ingredion Incorporated, and Global Chief Financial Officer of National Starch. Mr. Kieftenbeld started his career at Unilever in the Netherlands. Mr. Kieftenbeld earned a joint Master of Business Administration degree from New York University Stern School of Business, London School of Economics and Political Science, and the HEC School of Management, Paris. He holds a Bachelor of Science degree in Business Economics and Accounting from Windesheim University in the Netherlands.

Eduardo Alvarez

Eduardo Alvarez has served as our Chief Operating Officer since October 2017. Mr. Alvarez has over 30 years of global operations experience both running and advising growth companies. Previously, he served as Global Operations Strategy Leader for PricewaterhouseCoopers LLP (PwC). During his tenure, Mr. Alvarez co-led the integration of his prior company, Booz & Company, following its acquisition by PwC. In that role, he grew operations into a global practice with $1.5 billion in revenue and 4,000 employees. Mr. Alvarez’s assignments focused on delivering structural cost improvements while also driving sustained revenue growth. His experience also includes roles at Booz Allen Hamilton, General Electric and AT&T. Alvarez holds a Master of Business Administration degree from Harvard Business School, a Master’s of Science in Mechanical Engineering in Computer Control and Manufacturing from the University of California, Berkeley, and a Bachelor of Science degree in Mechanical Engineering from the University of Michigan. Mr. Alvarez is a board member of The Chicago Council of Global Affairs.

Nicole Kelsey

Nicole Kelsey has served as our General Counsel and Secretary since August 2017 and was recently appointed our Chief Legal Officer and Secretary. Ms. Kelsey has over 25 years of experience as an executive leader for public

 

32    AMYRIS, INC. 2021 PROXY STATEMENT

---

Table of Contents

Executive Officers

 

companies with international operations. Her areas of expertise range from international M&A to U.S. securities laws and multi-jurisdictional corporate governance, complex securities and commercial litigation, regulatory matters, investor and employee communications, and compliance. Prior to joining Amyris, she served as General Counsel and Secretary of Criteo, a global leader in commerce marketing based in Paris with global operations, for over three years. Prior to joining Criteo, Ms. Kelsey was the senior securities lawyer for Medtronic, a global leader in medical technology; she served as head M&A attorney for CIT Group, Inc.; was the general counsel and chief compliance officer of a private merchant bank; and was the senior corporate attorney for the international conglomerate Vivendi. Before going in-house, Ms. Kelsey practiced with the law firms of White & Case and Willkie, Farr & Gallagher, in Paris and New York. A Fulbright scholar, Ms. Kelsey holds a Juris Doctor degree from Northwestern Pritzker School of Law and a Bachelor of Arts degree in Political Science and International Studies from The Ohio State University, and is admitted to practice law in New York and Minnesota.

 

AMYRIS, INC. 2022 PROXY STATEMENT    33

---

Table of Contents

		Executive Compensation

 

Compensation Discussion and Analysis

The following discussion describes and analyzes the compensation policies, arrangements, and decisions for our named executive officers (or “NEOs”) in 2021 and should be read in conjunction with the compensation tables contained later in this Proxy Statement. We believe our existing compensation policies, arrangements and decisions are consistent with our compensation philosophy and objectives discussed below and align the interests of our NEOs with our short-term and long-term business objectives. During 2021, our NEOs were:

 

 

34    AMYRIS, INC. 2021 PROXY STATEMENT

---

Table of Contents

Executive Compensation  |  2021 Business Highlights

 

2021 Business Highlights

We are a high growth, biotechnology company at the forefront of delivering sustainable solutions that are better for people and the planet. To accelerate the world’s transition to sustainable consumption, we create, manufacture, and commercialize consumer products and ingredients that reach more than 300 million consumers. Currently, the largest driver of our revenue is derived from marketing and selling Clean Beauty & Personal Care and Health & Wellness consumer products through our direct-to-consumer ecommerce platforms and a growing network of retail partners. We also sell sustainable ingredients to sector leaders that serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets.

Our ingredients and consumer products are powered by our fermentation-based Lab-to-Market^TM technology platform. This technology platform drives the portfolio connection between our proprietary science and formulation expertise, our manufacturing capability at industrial scale, and our ability to commercialize sustainable products that make a difference in people’s lives. We believe that our technology platform offers advantages to traditional methods of sourcing similar ingredients (such as petrochemistry and extraction from organisms). Our technology platform allows for renewable and ethical sourcing of raw materials, less resource-intensive production, minimal impact on sensitive ecosystems, enhanced purity and safety profile, less vulnerability to climate disruption, and improved supply chain resilience. We bring together biology and engineering to generate more sustainable materials that would otherwise be scarce or endangered in nature. Our technology platform leverages state-of-the-art machine learning, robotics, and artificial intelligence, enabling us to rapidly bring new innovation to market.

We started 2021 with three consumer brands, Biossance^® clean beauty skincare, Pipette^® clean baby skincare, and Purecane^TM zero-calorie sweetener. During the second half of 2021, we launched five additional consumer brands in the Clean Beauty & Personal Care end market, including Terasana^® clean skincare, Costa Brazil^® luxury skincare, Olika^TM clean wellness, Rose Inc.^TM clean color cosmetics, and JVN^TM clean haircare.

In 2021, we delivered record total revenue of $342 million, representing a 97% increase over the prior year. We also delivered record consumer revenue of $32 million, an increase of 86% over the prior year, driven by strong performance from our three legacy brands, Biossance^®, Pipette^® and Purecane^TM, and solid early-stage performance of the newly launched brands, particularly Rose, Inc.^TM and JVN^TM. Our technology access revenue of $33 million increased by 54% compared to the prior year, driven by growth in technology license revenue, including our new joint ventures with ImmunityBio (vaccine) and Minerva Foods (protein). In November 2021, we sold $690 million convertible senior notes due 2026 which allowed us to simplify our capital structure, pay down restrictive debt arrangements, and provide working capital to support critical investments in R&D, product development, manufacturing and other initiatives as well as our long-term strategic goals.

 

AMYRIS, INC. 2022 PROXY STATEMENT    35

---

Table of Contents

Executive Compensation  |  Key Features of our Executive Compensation Program

 

Key Features of our Executive Compensation Program

 

✓ What We Do										Ñ What We Don’t Do
✓ Design executive compensation to align with performance   ✓ Balance short-term and long-term incentive compensation, with the majority of target total direct compensation being “at-risk” and in the form of performance-based compensation   ✓ Establish threshold and maximum levels of achievement for payouts under our annual cash bonus plan   ✓ 100% independent directors on our LDICC   ✓ Engage independent compensation consultant which reports directly to LDICC   ✓ LDICC meets regularly in executive session										Ñ  No excessive change in control or severance payments and benefits   Ñ  No “single-trigger” equity vesting acceleration   Ñ  No repricing of underwater stock options without stockholder approval   Ñ  No excessive perquisites   Ñ  No tax gross ups on severance change in control payments and benefits   Ñ  No retirement, pension or defined benefit plans that are not available to employees generally   Ñ  No guaranteed bonuses or base salary increases

Compensation Philosophy and Objectives

The primary objectives of our employee compensation program (including for our NEOs) in 2021 were to:

 

◾

Attract, retain, and motivate highly talented individuals that are key to our success;

 

◾

Support business strategy and motivate individuals to achieve outstanding business goals; and

 

◾

Support long-term company growth and enhance stockholder value.

Our success depends on, among other things, attracting and retaining executive officers with experience and skills in a number of different areas as we continue to drive improvements in our technology platform and production process, pursue and develop key commercial relationships, create and commercialize products, and establish a reliable supply chain and manufacturing organization.

Our business continues to be in an early stage of product development, with cash management being one key consideration for our strategy and operations. For 2021, we intended to provide a competitive compensation program that would enable us to attract and retain the top executive officers and employees necessary to develop our business, while being prudent in the management of our cash and equity. Based on this approach, we continued to aim to reward short-term and long-term performance with a total compensation package that included a mix of both cash and equity. Our compensation program was intended to align the interests of our executive officers, key employees and stockholders and to drive the creation of sustainable stockholder value by providing long-term incentive compensation in the form of equity awards, including performance-based equity awards with challenging price-based milestones.

Our intent and philosophy in designing compensation packages at the time of hiring new executive officers is based on providing compensation that we believe is sufficient to enable us to attract the necessary talent to grow our business, within prudent limits discussed above. The compensation of our executive officers following their initial hire is influenced by the amounts of compensation that we initially agreed to pay them, as well as by our evaluation of their subsequent performance, changes in their levels of responsibility, retention considerations, prevailing market conditions, our financial condition and prospects, and our attempt to maintain an appropriate level of internal pay parity in the compensation of existing executive officers relative to the compensation paid to more recently hired executive officers.

 

36    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Executive Compensation  |  Elements of Executive Compensation

 

Elements of Executive Compensation

We compensate our executive officers with fixed compensation (base salary) and variable compensation (cash bonuses and equity awards). We believe this combination of cash and equity compensation, subject to strategic allocation between these components, is largely consistent with the forms of compensation provided by other companies with which we compete for executive talent, and, as such, matches the expectations of our executive officers and the market for executive talent. We also believe that this combination provides appropriate incentive levels to retain our executive officers, reward them for performance in the short term and induce them to contribute to the creation of value in the Company over the long term. We view the different components of our executive compensation program as distinct, each serving particular functions in furthering our compensation philosophy and objectives, and together, providing a holistic approach to achieving such philosophy and objectives.

A significant portion of the target total direct compensation for our CEO and our other NEOs is structured as variable or “at-risk” compensation, with payouts and equity award values and vesting dependent upon the Company’s performance. This aligns our NEOs’ interests with those of our stockholders for near- and long-term performance.

 

 

 

AMYRIS, INC. 2022 PROXY STATEMENT    37

---

Table of Contents

Executive Compensation  |  Elements of Executive Compensation

 

 

38    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Executive Compensation  |  Compensation Decision-Making Process

 

Stockholder Say-on-Pay Votes

At our 2020 Annual Meeting of Stockholders, our stockholders voted, on an advisory basis, on the compensation of our NEOs (commonly referred to as a “stockholder say-on-pay vote”). In 2020, 98% of the votes cast on the stockholder say-on-pay proposal approved, on a non-binding advisory basis, the compensation of our NEOs as summarized in our 2020 Proxy Statement. The LDICC believes that this affirms our stockholders’ support of our approach to executive compensation. Accordingly, our executive compensation approach remained generally consistent in 2021 except for the addition of new performance-based equity awards to our CEO, CFO and COO, as described in more detail below under “2021 Compensation—Equity Awards—2021 Performance Equity Awards.” Our stockholders voted to approve the CEO’s performance-based equity award at our special meeting of stockholders in July 2021, which we believe affirmed their support for this grant.

In addition, in 2017 our stockholders approved, and our Board subsequently adopted, a three-year interval for conducting future stockholder say-on-pay votes. Our stockholders will again be voting, on an advisory basis, on the compensation of our NEOs at our 2023 Annual Meeting of Stockholders.

Compensation Decision-Making Process

Under the charter of the LDICC, our Board has delegated to the LDICC the authority and responsibility to discharge the responsibilities of our Board relating to the compensation of our executive officers. This includes, among other things, the review and approval of the compensation of our executive officers and of the terms of any compensation agreements with our executive officers. For more information regarding the functions and composition of the LDICC, please refer to “Proposal 1—Election of Directors—Board Committees and Meetings” above.

In general, the LDICC is responsible for the design, implementation, and oversight of our executive compensation program. In accordance with its charter, the LDICC determines the annual compensation of our CEO and other executive officers and reports its compensation decisions to our Board. The LDICC also administers our equity compensation plans, including our 2020 Equity Incentive Plan (the “2020 EIP”) and 2010 Employee Stock Purchase Plan. Generally, our Human Resources, Finance and Legal departments work with our CEO to design and develop new compensation programs applicable to our executive officers and non-employee directors, to recommend changes to existing compensation programs, to recommend financial and other performance targets to be achieved under those programs, to prepare analyses of financial data, to prepare peer compensation comparisons and other LDICC briefing materials, and to implement the decisions of the LDICC. Our Chief People Officer also meets separately with the LDICC’s compensation consultant, Compensia (as defined below), to convey information on proposals that management may make to the LDICC, as well as to allow Compensia to collect information about the Company to develop its recommendations. In addition, our CEO conducts reviews of the performance and compensation of our other executive officers, and based on these reviews and input from Compensia and our Human Resources department, makes recommendations regarding the annual total direct compensation for such executive officers directly to the LDICC. In the case of our CEO’s compensation, Compensia reviews and analyzes relevant competitive market data with the LDICC, and makes a recommendation regarding our CEO’s compensation to the LDICC.

Our Board has established a Management Committee for Employee Equity Awards (the “MCEA”), consisting of our Chief People Officer and our CFO. The MCEA may grant equity awards to employees or consultants who are not executive officers (as that term is defined in Section 16 of the Exchange Act and Rule 16a-1 promulgated under the Exchange Act) of the Company, provided that the MCEA is only authorized to grant equity awards that meet grant guidelines approved by our Board or the LDICC. These guidelines set forth, among other things, any limit imposed by our Board or the LDICC on the total number of shares of our common stock that may be subject to equity awards granted to employees or consultants by the MCEA, and any other requirements imposed by our Board or the LDICC.

 

AMYRIS, INC. 2022 PROXY STATEMENT    39

---

Table of Contents

Executive Compensation  |  Compensation Decision-Making Process

 

Role of Compensation Consultant

Under its charter, the LDICC has the authority, at the Company’s expense, to retain legal and other consultants, accountants, experts and compensation or other advisors of its choice to assist the LDICC in connection with its functions. Since 2012, the LDICC has retained Compensia, Inc. (“Compensia”), a national compensation consulting firm, to provide advice and guidance on our executive compensation policies and practices and relevant information about the executive compensation practices of similarly situated companies.

In connection with an annual review of our executive compensation program for 2021, Compensia provided the following services:

 

◾

reviewed and provided recommendations on the composition of our compensation peer group, and provided compensation data relating to certain executives at the selected peer group companies;

 

◾

conducted a review of the target total direct compensation arrangements for our executive officers;

 

◾

provided advice on executive officers’ compensation, including the composition of base salary, our short-term incentive (cash bonus) plan and long-term incentive (equity) plans;

 

◾

conducted a review of the annual cash retainers and equity incentive compensation opportunities for our non-employee directors under our non-employee director compensation program;

 

◾

assisted with the design of our 2021 performance-based equity awards for our CEO, CFO and COO, including an analysis of market trends and best practices relating to performance-based equity awards;

 

◾

updated the LDICC on emerging trends/best practices and regulatory requirements in the area of executive officer and non-employee director compensation, including cash and equity compensation;

 

◾

provided advice and recommendations regarding non-executive employee compensation equity awards;

 

◾

assisted in the preparation of materials for executive compensation proposals in advance of LDICC meetings, including 2021 compensation levels for certain of our executive officers and the design of our cash bonus, equity award, severance, and change in control programs and other executive benefit programs; and

 

◾

reviewed and advised the LDICC on materials relating to executive compensation prepared by management for LDICC consideration.

Compensia, under the direction of the LDICC, may continue to periodically conduct a review of the competitiveness of our executive officer compensation program, including base salaries, cash bonus opportunities, equity awards and other executive officer benefits, by analyzing the compensation practices of companies in our compensation peer group, as well as data from third-party compensation surveys. Generally, the LDICC uses the results of such analyses to assess the competitiveness of our executive officers’ target total direct compensation, and to determine whether each component of such target total direct compensation is properly aligned with reasonable practices among our peer companies.

The LDICC has also retained Compensia for assistance in reviewing and making recommendations to our Board regarding the compensation program for our non-employee directors and to provide competitive market data and materials with respect to non-employee director compensation to the LDICC.

In March 2021, the LDICC reviewed the independence of Compensia under applicable compensation consultant independence rules and standards and determined that Compensia did not have any relationships with the Company or any of its executive officers or directors or any conflicts of interest that would impair Compensia’s independence.

 

40    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Executive Compensation  |  2021 Peer Group

 

Use of Competitive Data

To monitor the competitiveness of our executive officers’ compensation, in November 2020, the LDICC approved a compensation peer group (the “Peer Group”) to be used in connection with its 2021 compensation deliberations that analyzed the compensation of executive officers in comparable positions at similarly-situated companies. In March 2021, based on a significant increase in our market capitalization, the LDICC approved changes to the Peer Group for its 2021 compensation deliberations. The data gathered from the Peer Group was used as one factor in setting executive officer pay levels (including cash and equity compensation), incentive plan practices, severance and change-in-control practices, equity utilization pay/performance alignment and non-employee director compensation.

In addition to reviewing the compensation practices of the Peer Group, the LDICC looks to the collective experience and judgment of its members and advisors, as well as relevant industry survey data, in determining the target total direct compensation and the various compensation components provided to our executive officers.

2021 Peer Group

The Peer Group for setting 2021 compensation included a cross-section of publicly traded, U.S.-based companies of similar size to us based primarily on revenue (less than $600 million) and enterprise value (between $800 million and $13 billion), with additional refinement criteria based on number of employees, R&D expenditures, and the related industries of the companies (biotechnology, life sciences, chemicals, food and personal products) and input from the LDICC and management. Based on these criteria, the following companies were included in the Peer Group approved in March 2021 by the LDICC for use in assessing the market position of our executive compensation for 2021:

 

2021 Peer Group
American Vanguard Balchem Berkeley Lights Beyond Meat Codexis		e.l.f. Beauty Freshpet Green Thumb Industries Hawkins Hims & Hers Health		Livent Medifast Phibro Animal Health Twist Bioscience USANA Health Sciences

While the LDICC does not believe that the Peer Group data is appropriate as a stand-alone tool for setting executive compensation due to the unique nature of our business, it believes that this information is a valuable resource during its decision-making process.

The LDICC references peer data as data points in its overall determination of our executive compensation program, but does not benchmark its compensation decisions to any particular level or against any specific member of the Peer Group. The LDICC believes the current total target compensation of our NEOs is reasonable and appropriate because we operate in a highly competitive and rapidly evolving market, and we expect competition among companies in our market to continue to increase. Our ability to compete and succeed in this environment is directly correlated to our ability to recruit, incentivize and retain talented individuals in the areas of product development, sales, marketing, services and general and administrative functions. The market for skilled personnel in these areas is very competitive and our LDICC believes that our current target level for total direct compensation is necessary to both retain our critical executive officers and attract top talent to contribute to the Company’s growth and success.

Equity awards have been a significant component in our overall compensation package, and we believe that they will remain an important tool for attracting, retaining and motivating our key talent by providing an opportunity for

 

AMYRIS, INC. 2022 PROXY STATEMENT    41

---

Table of Contents

Executive Compensation  |  Compensation Risk Management

 

ownership, participation and wealth creation as a result of our long-term success. To this end, in May 2021, the LDICC approved annual equity awards for our CFO and CLO and special performance-based equity awards for our CEO, CFO and COO, the details of which are described below under “2021 Compensation—Equity Awards—2021 Performance Equity Awards.” Our 2021 CEO performance equity award (the “CEO PSU Award”) was conditioned on the approval by our stockholders and was approved by our stockholders in July 2021.

In determining the size of the annual equity awards, the LDICC considered the retention value of existing awards held by our NEOs (taking into account option exercise prices and the prevailing market value of our common stock), the executive officers’ overall compensation packages, practices at the companies in the Peer Group and the responsibilities, performance, anticipated future contributions and retention risk of our NEOs. In determining the size of each of the 2021 Performance Equity Awards granted to certain of our NEOs the LDICC considered the criticality of each of their roles and low retention value of existing awards held by such NEOs.

Compensation Risk Management

In November 2020 and November 2021, the LDICC determined, through discussions with management and Compensia, that our policies and practices of compensating our employees, including our executive officers, are not reasonably likely to have a material risk to us. The assessments conducted by the LDICC focused on the key terms of our bonus plans and equity compensation programs in 2020 and 2021, and our plans for such programs in 2022, evaluating the risk factors in our compensation programs in four key areas—financial, operational, reputational, and talent. The LDICC focused on whether our compensation programs created incentives for risk-taking behavior and whether existing risk mitigation features and policies were sufficient in light of the overall structure and composition of our compensation programs. Among other things, the LDICC considered the following aspects of our overall compensation programs:

 

◾

Our cash bonus plan applies only to our executive officers and certain employees involved in sales activities and provides for a maximum total bonus funding available for payout of 120% of target funding, with payouts ranging from 0% to 200% of an individual’s target annual cash bonus opportunity, emphasizing Company performance over individual performance objectives.

 

Long-term equity compensation programs are designed to reward executives and other participants for driving sustainable and profitable growth for stockholders;

 

◾

Equity incentive awards for our executive officers have included different types of equity instruments, which helps to diversify the executive officers’ interests and limit excessive risk taking;

 

◾

The vesting periods for our time-based equity awards are designed to encourage executives and other participants to focus on sustained stock price appreciation;

 

◾

Our system of internal controls over financial reporting, standards of business conduct, and compliance programs reduce the likelihood of manipulation of our financial performance to enhance payments under our bonus and sales compensation plans;

 

◾

We have a clawback or recoupment policy for certain performance-based incentive compensation of our executive officers; and

 

◾

Our Insider Trading Policy prohibits all employees from pledging stock, engaging in short sales, or hedging transactions involving our stock.

Based on these considerations, the LDICC determined that our compensation programs, including our executive and non-executive compensation programs, provide an appropriate balance of incentives and do not encourage our executive officers or other employees to take excessive risks or otherwise create risks that are likely to have a material adverse effect on us.

 

42    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Executive Compensation  |  2021Compensation

 

2021 Compensation

Background

In designing the compensation program and making decisions for our executive officers for 2021, the LDICC sought to balance achievement of critical operational goals with retention of key personnel, including our executive officers. Accordingly, the LDICC focused in particular on implementing a robust equity compensation program in order to provide strong retention incentives in a challenging and highly competitive environment for top talent. It also focused on cash management in setting target total cash compensation (including base salary and target annual cash bonus opportunity levels) for our executive officers. Another key theme for 2021 was establishing strong incentives to drive our performance, including continued emphasis on Company performance goals over individual goals in the 2021 cash bonus plan and on equity compensation for longer-term upside potential and sharing in Company growth.

Base Salaries

During 2021, the LDICC reviewed the base salaries, target annual cash bonus opportunities and target total cash compensation of our executive officers against our Peer Group and industry survey data, and as a result of such analysis, as well as consideration of the factors described above under “Compensation Philosophy and Objectives and Elements of Compensation—Base Salary,” approved (a) an increase to the base salary of Mr. Melo from $650,000 to $750,000 effective May 16, 2021, in recognition of his criticality to driving the Company’s strategic growth and investment initiatives, (b) an increase to the base salary of Mr. Kieftenbeld from $420,000 to $460,000 effective April 1, 2021, in recognition of his expanded role as the Company’s Chief Administration Officer and in alignment with general market increases, and (c) an increase to the base salary of Ms. Kelsey from $395,000 to $425,000, effective May 16, 2021, to remain in line with our targeted competitive market for total cash compensation. Mr. Alvarez’s base salary remained unchanged in 2021.

Cash Bonuses

In November 2020, the LDICC approved the 2021 cash bonus plan architecture for our executive officers consistent with the cash bonus plan for 2020, pending the approval of quarterly and annual target levels for each performance metric upon finalization of the Company’s business plan for 2021. In May 2021, the target levels for the performance metrics were approved and the weighting of certain performance metrics selected for use in the 2021 cash bonus plan was amended, as further detailed below.

Under the 2021 cash bonus plan, our executive officers were eligible for cash bonuses based on the achievement of Company performance metrics for each quarter in 2021, with a portion of their annual target cash bonus opportunities allocated to annual Company and individual performance. The 2021 cash bonus plan provided for funding and payout of cash bonus awards if the Company achieved target levels set for GAAP revenue (both quarterly and annual), operating expense (both quarterly and annual), product gross margin (quarterly) and total gross margin (annual). For purposes of the 2021 bonus plan, “GAAP revenue” means total Company revenue as reported, “operating expense” means total cash operating expense (i.e., excludes such items as depreciation and amortization and stock compensation), “product margin” means margin generated relative to product related revenue, and “gross margin” means margin generated relative to total revenue. Payouts under the 2021 cash bonus plan were made following a review of our results and performance each quarter and, for the fourth quarter and annual components, following a review that occurred in March 2022. The 2021 cash bonus plan provided for a 60% weighting for quarterly achievement (with each quarter worth 15% of the total bonus fund for the year) and 40% for full year achievement. The 2021 cash bonus plan and the selection of these performance metrics intended to provide a balanced focus on both our long-term strategic goals and shorter-term quarterly operational goals.

The total funding possible under the 2021 cash bonus plan was based on a cash value (or the “target bonus fund”) determined by the executive officers’ target annual cash bonus opportunities. The target annual cash bonus

 

AMYRIS, INC. 2022 PROXY STATEMENT    43

---

Table of Contents

Executive Compensation  |  2021Compensation

 

opportunities for our executive officers in 2020 varied by individual, but were generally set between 50% and 100% of their annual base salary. In May 2021, in connection with the Board’s review of the annual 2021 Company business plan and budget, the LDICC reviewed our executive officers’ target annual cash bonus opportunities as part of its review of target total cash compensation for similar roles among executive officers at companies in the Peer Group, as supplemented by relevant industry survey data, and, as a result of such analysis, as well as consideration of the factors described above under “Compensation Philosophy and Objectives and Elements of Compensation—Cash Bonuses,” approved no changes to the target annual cash bonus opportunities for our executive officers.

The quarterly and annual funding of the 2021 cash bonus plan was based on achievement of the following company performance metrics for the applicable quarter and full year 2021: GAAP revenue (weighted 50% for each quarterly and annual period), operating expenses (weighted 20% for each quarterly and annual period), product gross margin (weighted 30% for the quarterly period), and total gross margin (weighted 30% for the annual period). For each quarterly period and for the annual period under the 2021 cash bonus plan, “threshold,” “target,” and “superior” performance levels were set for each applicable performance metric, which performance levels were intended to capture the relative difficulty of achievement of that metric. In May 2021, the weighting of the operating expense and product gross margin and total gross margin metrics were recalibrated to reflect the impact on such performance metrics by consumer brands’ growth and increased investment in the selling and marketing efforts to support the Company’s brand growth, due to expected launch of five additional consumer brands in the second half of 2021. Prior to the amendment, operating expenses was weighted at 30% for each quarterly and annual period, and product/total gross margin was weighted at 20% for the quarterly and annual periods.The associated targets of each of these two metrics were not modified such that the same levels of achievement were required. The LDICC determined that it was reasonable and necessary to recalibrate of the weighting of these two metrics in order for the 2021 cash bonus plan to reflect the Company’s investment in the Company’s brand growth as noted above, and to preserve incentive and retentive value at a time when employee engagement and focus are critical. The LDICC did not modify the weighting of GAAP revenue, which comprises the largest portion of the 2021 cash bonus plan. The 2021 cash bonus plan remained challenging and difficult to achieve without meaningful effort.

As shown below, if we were to achieve the “minimum” level for any performance metric, we would receive 50% funding for that metric. If the collective funding of all performance metrics was below 50%, we would receive no funding. If we were to achieve between the “minimum and “target” levels for any performance metric, we would receive pro rata funding between 50% and 100% for that metric. If we were to achieve between the “target” and “maximum” levels for any performance metric, we would receive pro rata funding between 100% and 200% for that metric. Funding was capped at 200% of target for each performance metric regardless of performance exceeding the “maximum” level.

 

						Performance Range												Payout Range
Performance Metrics		Weight				Min				Target				Max				Min				Target				Max
GAAP Revenue ($m)			50%				80%				100%				120%				50%				100%				200%
Operating Expenses ($m)			20%				90%				100%				110%				50%				100%				200%
Product/Total Gross Margin(1) %			30%				90%				100%				110%				50%				100%				200%

(1)	Product gross margin for each quarterly period and total gross margin for the annual period.

Any payouts for the quarterly bonus periods would be the same as the funded level (provided the recipient meets eligibility requirements), subject to the final approval of the LDICC. Payouts for the annual bonus period would be made from the aggregate funded amount based on Company and individual performance, and could range from 0% to 200% of an individual’s funded amount for the annual bonus period.

The LDICC chose to emphasize Company performance goals for the quarterly and annual bonus plan periods given the critical importance of our short-term strategic goals, but also to retain reasonable incentives and rewards for

 

44    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Executive Compensation  |  2021Compensation

 

exceptional individual performance, recognizing the value of such incentives and rewards to our operational performance and to individual retention.

Based on the foregoing bonus plan structure, individual bonuses were awarded each quarter based on the LDICC’s assessment of Company achievement, and with respect to the annual bonus, the LDICC’s assessment of Company achievement as well as each executive officer’s contributions to such achievement, his or her progress toward achieving his or her individual performance goals, and his or her demonstrating our core values. Actual payment of any bonuses with respect to 2021 remained subject to the final approval of the LDICC.

Company Performance Metrics. The quarterly and annual weighting and actual achievement level for each Company performance metric are described below.

The applicable target levels for each quarter were discussed and evaluated based on quarterly and annual performance and continued development of our business and operating plans for 2021 and beyond. In March 2022, the LDICC discussed and evaluated the fourth quarter 2021 as well as the full year 2021 results. Achievement levels were approved by the LDICC following each period under the 2021 annual cash bonus plan. The annual and fourth quarter target levels were amended by the LDICC in November 2021 to reflect new revenue guidance provided internally and externally. Due to supply chain challenges in the third and fourth quarters of 2021, including access to packaging components and ingredients, our full year 2021 revenue estimate was reduced in November 2021. As a result, the LDICC reviewed the GAAP revenue target performance metric and approved amendments to the minimum, target and maximum levels of such performance metric for the fourth quarter and annual periods to (i) maintain the alignment of such metric with revenue guidance provided to the market, while still maintaining GAAP revenue as a challenging goal for such periods, and (ii) continue the effectiveness of the 2021 bonus plan as an incentive and retention tools not only to our NEOs but also to the other employees under such plan, especially given the highly competitive market in which we operate.

Degree of Difficulty in Achieving Performance Goals. The LDICC considered the likelihood of achievement when recommending and approving, respectively, the Company and individual performance goals and bonus plan structures for each of the 2021 annual cash bonus plan periods, but it did not undertake a detailed statistical analysis of the difficulty of achievement of each measure. For 2021, the LDICC considered the 70% weighted average achievement level to be attainable with normal effort, 100% to be challenging but achievable with significant effort, requiring circumstances to align as predicted, and any amounts in excess of 100% to be difficult to achieve, requiring additional sources of revenue, breakthroughs in technology, manufacturing operations and process development, business development, and exceptional levels of effort on the part of the executive leadership team, as well as favorable external conditions.

 

AMYRIS, INC. 2022 PROXY STATEMENT    45

---

Table of Contents

Executive Compensation  |  2021Compensation

 

2021 Quarterly and Annual Bonus Plan Funding and Award Decisions. In each of May 2021, August 2021, November 2021 and March 2022, the LDICC determined that our quarterly and annual performance goals were achieved as follows:

 

Company Performance Goal		Weight				Weighted Achievement Level				Funding Level
Q1
GAAP Revenue			50	%			48	%
Operating Expenses			20	%			19	%
Product Gross Margin			30	%			60	%
Total Q1			100	%			127	%			127	%
Q2
GAAP Revenue			50	%			31	%
Operating Expenses			20	%			25	%
Product Gross Margin			30	%			0	%
Total Q2			100	%			56	%			85	%(1)
Q3
GAAP Revenue			50	%			0	%
Operating Expenses			20	%			0	%
Product Gross Margin			30	%			0	%
Total Q3			100	%			0	%			64	%(1)
Q4
GAAP Revenue			50	%			59	%
Operating Expenses			20	%			0	%
Product Gross Margin			30	%			0	%
Total Q4			100	%			59	%			85	%(1)
ANNUAL
GAAP Revenue			50	%			51	%
Operating Expenses			20	%			12	%
Total Gross Margin			30	%			37	%
Total Annual			100	%			100	%			99	%

(1)	The LDICC approved discretionary increases in the cash bonus paid to all eligible participants under the cash bonus plan, including the named executive officers, for the quarterly bonus payments in the second, third and fourth quarters of 2021 as discussed below.

Individual Performance Goals. For the annual portion of the 2021 cash bonus plan tied to individual performance, the LDICC considered several factors, including the following:

 

◾

Our CEO’s performance reflects his overall leadership of the Company. Under his leadership, the Company delivered strong year-over-year sales revenue growth, oversaw strategic partnerships and new brand launches, enhanced customer impact, and improved overall Company operations. Importantly, he also led on advancing strategic initiatives and transactions for the Company.

 

◾

Our CFO’s performance reflects his leadership of the Company’s finance, human resources, IT, corporate communications, investor relations, and ESG functions. Under his leadership, the Company made significant improvements in our financial processes, internal controls, cash management, and investor relations activities. He oversaw a successful recapitalization of the Company’s balance sheet, including the planning and execution of large, complex equity and debt offerings. He led the Company’s inaugural ESG report and has been instrumental in the completion of strategic transactions, M&A and new brand launches.

 

46    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Executive Compensation  |  2021Compensation

 

◾

Our COO’s performance reflects his leadership of the Company’s manufacturing, engineering, environmental health & safety, and supply chain functions. Under his leadership, the Company is on track to complete construction of the new Brazil manufacturing facility, and the Company continued to demonstrate a strong safety track record and scale the development of molecules into production, launched new consumer brands and improved consumer brand supply chain operations.

 

◾

Our CLO’s performance reflects her leadership of the Company’s legal and compliance functions. Under her leadership, the Legal function provided critical support for the execution of strategic partnerships, M&A transactions, and equity and debt financing transactions, the launch of new brands, the management of ongoing litigation and investigation matters, leadership on the Company’s ESG and DEI initiatives, and improvements in the Company’s compliance program.

The LDICC considered individual and company performance in approving the following cash bonus awards under the 2021 cash bonus plan:

 

Name		2021 Cumulative Quarterly Bonus Payouts ($)					2021 Annual Portion Bonus Payout ($)					2021 Aggregate Annual and Quarterly Bonus Payouts ($)					Annual Bonus Target ($)					2021 Actual Bonus Earned as a %  of Target Bonus
John Melo				250,980					445,500					696,480				$	730,000					95	%
Han Kieftenbeld				151,712					282,348					434,060				$	447,700					97	%
Eduardo Alvarez				191,950					396,000					577,950				$	500,000					116	%
Nicole Kelsey				74,037					84,150					158,187				$	209,500					76	%

We believe that the payment of these awards was appropriate because the 2021 cash bonus plan appropriately held our NEOs accountable for achievement of Company and individual goals, and the payouts were reasonable and appropriate in light of our progress towards our business objectives. With respect to the quarterly bonus payments in the second, third and fourth quarters of 2021, the LDICC, to recognize the effective execution and significant progress made on certain critical business goals, in its discretion approved amounts in excess of the applicable funded levels under the cash bonus plan, which resulted in additional cash bonus payouts to each of our NEOs in the amount of $132,650 in the aggregate to Mr. Melo, $82,248 in the aggregate to Mr. Kieftenbeld, $89,400 in the aggregate to Mr. Alvarez, and $37,778 in the aggregate to Ms. Kelsey, as reflected in the “Summary Compensation Table” below.

Performance Bonuses. In addition, in May 2021, the LDICC approved cash bonuses of (a) $400,000 to Mr. Melo in recognition of his extraordinary efforts in negotiating, structuring and consummating certain transformative transactions for the Company in the first quarter of 2021, including the sale of exclusive rights to the Company’s flavor and fragrance product portfolio DSM Nutritional Products Ltd., (b) $100,000 to Mr. Kieftenbeld in recognition of his extraordinary efforts in procuring and negotiating a licensing transaction with Ingredion Incorporated, and (c) $75,000 to Mr. Alvarez in recognition of his extraordinary efforts in assisting in the negotiation and closing of the transaction with Ingredion Incorporated. In December 2021, the LDICC approved a cash bonus of $5,000 to Ms. Kelsey in recognition of her efforts in resolving a government investigation.

Equity Awards

The LDICC approved equity awards for the executive officers consisting of time-based focal awards, performance-based equity awards, and one-time recognition awards, as described below.

2021 Focal Equity Awards. With respect to the focal awards, the LDICC determined the allocation of equity awards between stock options and RSU awards after consultation with Compensia, in evaluating the practices of our Peer Group and survey data and in consultation with management, taking into consideration, among other

 

AMYRIS, INC. 2022 PROXY STATEMENT    47

---

Table of Contents

Executive Compensation  |  2021Compensation

 

things, the appropriate balance between rewarding previous performance, retention objectives, upside value potential tied to our and the executive officer’s future performance and the mix of the executive officer’s current vested and unvested equity holdings. The size of the focal awards varied among the applicable NEOs based on the value of unvested equity awards already held by him or her, his or her relative contributions during 2020, and anticipated levels of responsibility among the NEOs for key corporate objectives in 2021.

In May 2021, the LDICC approved (i) a focal award to Mr. Kieftenbeld of an RSU award covering 100,000 units subject to the terms described below and (ii) a focal award to Ms. Kelsey of an RSU award covering 37,500 units and an option to purchase 12,500 shares of our common stock subject to the terms described below. In lieu of time-based focal awards, Messrs. Melo and Alvarez received performance-based equity awards as described below.

In accordance with our policy regarding equity award grant dates, the focal awards to Mr. Kieftenbeld and Ms. Kelsey were granted on May 24, 2021, the first business day of the week following the week in which such awards were approved, with the exercise price of the stock option granted to Ms. Kelsey set at $13.39 per share, the closing price of our common stock on Nasdaq on such date, in accordance with the terms of the 2020 EIP. This stock option vests over four years, with 25% of the shares subject to the option vesting one year from the vesting commencement date on May 24, 2021, and the remainder vesting over the following three years in equal monthly installments. The RSU awards to Mr. Kieftenbeld and Ms. Kelsey vest in three equal annual installments on June 1 of each of 2022, 2023 and 2024. Each unit granted pursuant to the focal awards represents a contingent right to receive one share of our common stock for each unit that vests.

2021 Performance Equity Awards. We believe that granting performance-based RSU awards incentivizes our executive officers in a manner that aligns their interests with our long-term strategic direction and the interests of our stockholders in support of long-term value creation. As such, in May 2021, the LDICC and our Board approved, as applicable (the “2021 Performance Equity Awards”):

 

◾

CEO PSU Award: a grant to Mr. Melo of a performance-vesting restricted stock unit award representing the right to receive up to 6,000,000 shares of our common stock under our 2020 EIP based on the achievement of four specified stock price performance metrics (as detailed below) over a four-year period, contingent upon approval by our stockholders of the CEO PSU Award, which approval was obtained at our 2021 special meeting of stockholders held on July 26, 2021. Upon approval of the CEO PSU Award, the 2018 CEO PSO (as described below) was automatically cancelled and forfeited.

 

◾

CFO PSU Award: a grant to Mr. Kieftenbeld of a performance-vesting restricted stock unit award (the “CFO PSU Award”) representing the right to receive up to 300,000 shares of our common stock under our 2020 EIP on substantially the same terms as the CEO PSU Award.

 

◾

COO PSU Award: a grant to Mr. Alvarez of a performance-vesting restricted stock unit award (the “COO PSU Award”) representing the right to receive up to 600,000 shares of our common stock under our 2020 EIP subject to the achievement of certain highly strategic operational goals (as detailed below) prior to December 31, 2022.

In accordance with our policy regarding equity award grant dates, the COO PSU Award was granted on May 24, 2021, and the CEO PSU Award and the CFO PSU Award were granted on August 2, 2021, the first business day of the week following the week in which the CEO PSU Award was approved by our stockholders.

In structuring the 2021 Performance Equity Awards, our Board and the LDICC, in consultation with Compensia, considered at length which performance metrics would both meaningfully drive Company performance and create significant stockholder value. Our Board and the LDICC considered a variety of factors, including, our continued growth, the highly competitive and dynamic synthetic biotechnology industry and the difficulty of predicting future performance in such an environment. In establishing the stock price-based performance metric of the CEO PSU

 

48    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Executive Compensation  |  2021Compensation

 

Award and the CFO PSU Award, our Board and the LDICC took into consideration a variety of factors, including the Company’s growth trajectory. Accordingly, our Board and the LDICC concluded that a performance metric requiring the sustained achievement of increasing share prices over a four-year performance period best enabled the Company to incentivize Messrs. Melo and Kieftenbeld over a longer-term horizon and align their respective success with that of our stockholders. In determining the size and operational performance metrics of the COO PSU Award, the LDICC considered the retention value of existing awards held by Mr. Alvarez and the strategic relevance of certain operational goals to the Company’s objectives and concluded that the performance metrics under the COO PSU best incentivizes and retains Mr. Alvarez until the completion and full operation of the Company’s manufacturing plant in Barra Bonita, Brazil and the facility in Reno, Nevada.

Our Board and the LDICC believe the selected structure and terms of the 2021 Performance Equity Awards (as described in detail below) will motivate our CEO, CFO, and COO to perform against challenging and reasonably aggressive targets in alignment with our stockholders and will reward each of them for taking actions today that will create sustainable value for our stockholders for years to come. Our Board and the LDICC also reviewed similar performance-based equity awards and total executive compensation of other public companies’ executives as a reference point for determining the size and terms of the 2021 Performance Equity Awards.

Upon our stockholders’ approval, and immediately prior to the effectiveness of the CEO PSU Award, the performance-based stock option to purchase up to 3,250,000 shares of our common stock granted to Mr. Melo in 2018 (the “2018 CEO PSO”) was automatically cancelled and forfeited. In proposing the CEO PSU Award, the LDICC considered that the performance metrics of the 2018 CEO PSO had not been achieved and could not be achieved prior to the conclusion of its term, due to changes in the Company’s business and, as such, it no longer provided the intended incentive and retentive value for our CEO, whose leadership is critical to guide the Company through an unprecedented period of growth, transformation and innovation, including strategic partnerships and new brand launches. The LDICC also reviewed the size and vesting schedule for the remaining unvested portion of all other outstanding equity awards held by our CEO and determined that they were likewise insufficient to effectively incentivize performance and retention.

CEO PSU Award and CFO PSU Award

The CEO PSU Award and CFO PSU Award are performance-based RSU awards with a direct relationship between the value of the equity awards and the fair market value of our common stock, thus Messrs. Melo and Kieftenbeld will receive compensation from their respective awards only to the extent that the Company achieves the applicable stock price-based performance milestones.

Performance Metrics & Vesting. The CEO PSU Award and the CFO PSU Award will be eligible to vest if the Company achieves four separate stock price-based performance metrics (each, a “Stock Price Metric”) from the date of grant through July 1, 2025 (the “Performance Period”) and any portion of the CEO PSU Award or the CFO PSU Award, as applicable, for which performance is achieved will vest subject to Messrs. Melo or Kieftenbeld’s continued service as our CEO and CFO, respectively (“CEO/CFO Service”), with certain limited exceptions, as discussed below.

Stock Price Performance Metrics. Each of the CEO PSU Award and CFO PSU Award are divided into four equal tranches as described in the Performance Metrics Table below (each a “Tranche”). If the Target Volume Weighted Average Price, or “Target VWAP,” as described below, applicable to a Tranche is achieved during the Performance Period, that Tranche’s shares will become eligible to vest subject to the applicable CEO/CFO Service on the applicable vesting dates, as discussed below. The units underlying any Tranche for which performance has been

 

AMYRIS, INC. 2022 PROXY STATEMENT    49

---

Table of Contents

Executive Compensation  |  2021Compensation

 

achieved and that are eligible to vest over time are referred to as “Eligible RSUs.” Each unit granted pursuant to the CEO PSU Award and the CFO PSU Award represents a contingent right to receive one share of our common stock for each unit that vests.

 

Performance Metrics Table
Tranche		Target VWAP		CEO PSU Total Tranche RSUs		CFO PSU Total Tranche RSUs		Earliest Vesting Commencement Date
“Tranche 1”		$22.00		1,500,000 RSUs		75,000 RSUs		Not Applicable
“Tranche 2”		$27.00		1,500,000 RSUs		75,000 RSUs		July 1, 2023
“Tranche 3”		$32.00		1,500,000 RSUs		75,000 RSUs		July 1, 2024
“Tranche 4”		$37.00		1,500,000 RSUs		75,000 RSUs		July 1, 2025
Total:				6,000,000 RSUs		300,000 RSUs

The Stock Price Metric for a Tranche is achieved if the VWAP of our common stock for both a 120-trading day period and the 30-trading day period ending on the final day of the 120-trading day period equal or exceed the Target VWAP set forth in the Performance Metrics Table for such Tranche during the Performance Period. The Tranches will be measured separately and multiple Tranches may be achieved simultaneously.

Our Board or the LDICC will certify whether the Stock Price Metric for any Tranche has been met.

The Target VWAP will be adjusted to reflect events such as a stock split or recapitalization in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the CEO PSU Award and the CFO PSU Award, as applicable.

As further discussed above, our Board and the LDICC consider the Stock Price Metrics to be a challenging hurdle. Our Board and the LDICC set the Stock Price Metrics to drive enhanced stockholder returns, and to further align Messrs. Melo and Kieftenbeld’s compensation opportunities to long-term stockholder interests.

Time-Based Vesting Following Achievement of the Stock Price Metric. Upon our Board’s or LDICC’s certification of achievement of a Tranche’s Stock Price Metric, 25% of the shares in such Tranche will vest with the remaining 75% vesting over the three subsequent quarters. For all but the first of the four Tranches, vesting will commence no earlier than “Earliest Vesting Commencement Date” for such Tranche set forth in the Performance Metrics Table above. If the Stock Price Metric is achieved after the Earliest Vesting Commencement Date, the vesting schedule will commence on the next occurring July 1, October 1, January 1 or April 1. For the first Tranche only, upon achievement of the Stock Price Metric, the vesting schedule will commence on the next occurring July 1, October 1, January 1 or April 1.

Employment Requirement for Continued Vesting. Messrs. Melo or Kieftenbeld, as applicable, must be providing CEO/CFO Services at the time of the achievement of a Tranche’s Stock Price Metric to be eligible to vest in the resulting Eligible RSUs. Mr. Melo must be employed by the Company, as its CEO, and Mr. Kieftenbeld must be employed by the Company, as its CFO, or, in both cases, in another employment position, on each applicable time-based vesting date following the achievement of the applicable Stock Price Metric.

Termination of Employment. Except in the context of a change of control of the Company, there will be no acceleration of vesting of the CEO PSU Award or the CFO PSU Award if the employment of Mr. Melo or Mr. Kieftenbeld, respectively, is terminated, or if they die or become disabled. In other words, termination of Mr. Melo or Mr. Kieftenbeld’s employment with the Company will preclude their respective ability to earn any then-unvested portion of the CEO PSU Award or CFO PSU Award, as applicable, following the date of his termination.

 

50    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Executive Compensation  |  2021Compensation

 

Change of Control. If the Company experiences a change of control, such as a merger with or purchase by another company, vesting under the CEO PSU Award and CFO PSU Award will not automatically accelerate.

In the event of a change of control of the Company, the performance under the CEO PSU Award and the CFO PSU Award will be determined as of the change of control. For this change of control determination, a Stock Price Metric relating to any Tranche that has not yet been achieved prior to the change of control will be deemed achieved if the per share price (plus the per share fair market value of any other consideration) received by our stockholders in the change of control equals or exceeds the applicable Stock Price Metric. To the extent a Stock Price Metric for a Tranche is achieved upon a change of control, the shares specified for such Tranche will be subject to time-based vesting (the “COC Time-Based RSUs”), and such COC Time-Based RSUs will vest in four equal installments, with the first installment vesting upon the later of the date of the change of control and the Earliest Vesting Commencement Date applicable to such Tranche as set forth in the Performance Metrics Table above and quarterly thereafter (except that the first Tranche will commence vesting on the date of the change of control and quarterly thereafter), subject to the CEO/CFO Service on each such vesting date.

Notwithstanding the foregoing, if the employment of either of Mr. Melo or Mr. Kieftenbeld is terminated without cause or he resigns for good reason in connection with the change of control, any then-unvested Eligible RSUs and then-unvested COC Time-Based RSUs will accelerate, subject to his satisfaction of certain terms and conditions, including, but not limited to delivery of a release of claims, pursuant to the terms of the Severance Plan (as described below) and his related participation agreement thereunder.

To the extent a Stock Price Milestone for a Tranche is not achieved as a result of the change of control of the Company, such Tranche will be forfeited automatically immediately prior to closing of the change of control and will never become vested.

The 2020 EIP provides that any or all outstanding awards issued thereunder, including the CEO PSU Award and CFO PSU Award, may be continued, assumed or substituted (including, but not limited, with payment in cash) by the successor or acquiring corporation (if any) in a change of control of the Company. If the successor or acquiring corporation (if any) of the Company refuses to assume, convert, replace or substitute the CEO PSU Award and CFO PSU Award in connection with a change of control, 100% of Messrs. Melo and Kieftenbeld’s then-unvested Eligible RSUs and then-unvested COC Time-Based RSU will accelerate and become vested effective immediately prior to the closing of the change of control.

The treatment of the CEO PSU Award and CFO PSU Award upon a change of control of the Company is intended to align Messrs. Melo and Kieftenbeld’s interests with the Company’s other stockholders with respect to evaluating potential change of control offers.

Tax Withholding. Unless determined otherwise by the LDICC in advance of any vesting date, the tax withholding obligations owed upon settlement of any portion of the CEO PSU Award and CFO PSU Award will be paid by a “broker-assisted” or “same-day sale.”

Clawback. In the event of a restatement of the Company’s financial statements previously filed with the SEC as a result of material noncompliance with financial reporting requirements (“restated financial results”) that results in a decline of the trading prices of our common stock below the Stock Price Metrics and it is determined to be necessary to complete such a restatement prior to December 31, 2028, the Company may require forfeiture (or repayment, as applicable) of the portion of the CEO PSU Award and/or CFO PSU Award in excess of what would have been earned or paid based on the restated financial results (whether or not the CEO and/or CFO remains an employee of the Company at such time).

 

AMYRIS, INC. 2022 PROXY STATEMENT    51

---

Table of Contents

Executive Compensation  |  2021Compensation

 

COO PSU Award

The COO PSU Award is a performance-vesting RSU award with a direct relationship between the value of the equity awards and the achievement of certain highly strategic operational goals to the Company prior to December 31, 2022. Thus, Mr. Alvarez will receive compensation from his award only to the extent that the Company timely achieves six separate operational performance metrics related to product production, brand launch, and manufacturing facility development (each, a “COO Performance Metric”) from January 1, 2021 through December 31, 2022 (the “COO Performance Period”). Each unit granted pursuant to the COO PSU Award represents a contingent right to receive one share of our common stock for each unit that vests.

Performance Metrics & Vesting. The COO PSU Award, which is up to 600,000 shares of our common stock, is divided into six tranches as described below (each a “COO Tranche”). If the COO Performance Metric applicable to a COO Tranche is achieved during the COO Performance Period, that Tranche’s shares will vest. The units underlying any Tranche for which performance has been achieved are referred to as “Eligible RSUs.”

Two of the COO Tranches relate to our Reno plant. 90,000 shares under the COO PSU Award will vest upon achievement of each of the following relating to our Reno plant: (i) certain production goals by December 31, 2021, (ii) certain production transitions by December 31, 2021, and (iii) certain plant commission and scale goals by December 31, 2022.

Four of the COO Tranches relate to our Barra Bonita plant. 144,000 shares under the COO PSU Award will vest upon achievement of certain construction goals by January 31, 2022. 96,000 shares under the COO PSU Award will vest upon certain plant commission goals by March 31, 2022. 90,000 shares under the COO PSU Award will vest upon achievement of each of the following: (i) certain contract transfer and production plan goals by December 31, 2022, and (ii) certain production goals by December 31, 2022.

The details of the COO PSU Award goals pertain to confidential company development and business plans, the disclosure of which in any additional granularity would result in competitive harm to the Company. Our Board and the LDICC believed that each of these goals would be significantly challenging and would require a high level of performance in order to be achieved.

The LDICC will certify whether the COO Performance Metric for any COO Tranche has been met after the conclusion of the COO Performance Period. There will be no partial or additional achievement to the extent achievement is below or above the target COO Performance Metric achievement specified above. Multiple COO Performance Metrics may be achieved simultaneously. The Eligible RSUs will vest two weeks following the certification date, subject to Mr. Alvarez’s continuous service.

Employment Requirement for Continued Vesting. Mr. Alvarez must be providing services at the time the LDICC certifies achievement of a COO Tranche, with the COO Performance Metric eligible to vest in the resulting shares.

Termination of Employment. Except in the context of a change of control of the Company, there will be no acceleration of vesting of the COO PSU Award in the event of termination, death, or disability. In other words, termination of Mr. Alvarez’s employment with the Company will preclude his ability to earn any then-unvested portion of the COO PSU Award following the date of his termination.

Change of Control. If the Company experiences a change of control during the COO Performance Period, such as a merger with or purchase by another company, the COO Performance Metric for any COO Tranche that has not yet been achieved will be deemed achieved effective as of immediately prior to the closing of the change of control (such resulting RSUs, the “COO COC RSUs”). The COO COC RSUs will be unvested on the closing date and will vest on December 31, 2022, subject to Mr. Alvarez’s continuous service on the closing date and on such vesting date.

 

52    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Executive Compensation  |  Other Compensation Elements

 

Notwithstanding the foregoing, if the employment of Mr. Alvarez is terminated without cause or he resigns for good reason in connection with the change of control of the Company, any then-unvested COO COC RSUs will accelerate, subject to Mr. Alvarez’s satisfaction of certain terms and conditions, including, but not limited to delivery of a release of claims, pursuant to the terms of the Severance Plan (as described below) and his related participation agreement thereunder.

The 2020 EIP provides that any or all outstanding awards issued thereunder, including the COO PSU Award, may be continued, assumed or substituted (including, but not limited, with payment in cash) by the successor or acquiring corporation (if any) in a change of control of the Company. If the successor or acquiring corporation (if any) of the Company refuses to assume, convert, replace or substitute the COO PSU in connection with a change of control, 100% of Mr. Alvarez’s then-unvested COO COC RSUs will accelerate and become vested effective immediately prior to closing of the change of control.

The treatment of the COO PSU Award upon a change of control of the Company is intended to align Mr. Alvarez’s interests with our other stockholders with respect to evaluating potential change of control offers.

Tax Withholding. Unless determined otherwise by the LDICC in advance of any vesting date, the tax withholding obligations owed upon settlement of any portion of the COO PSU Award will be paid by a “broker-assisted” or “same-day sale.”

Clawback. The COO PSU Award is subject to clawback or recoupment pursuant to any compensation clawback or recoupment policy adopted by our Board or as required by law during the term of Mr. Alvarez’s service or other service that is applicable to him. In addition to any other remedies available under such policy, applicable law may require the cancellation of the COO PSU Award (whether vested or unvested) and the recoupment of any gains realized with respect to such award.

2021 Recognition Equity Awards. In May 2021, the LDICC granted Mr. Melo an RSU award to acquire 149,365 shares, with an approximate grant date value of $2 million, vesting immediately, in recognition of his extraordinary efforts in negotiating, structuring and consummating certain transformative transactions for the Company in the first quarter of 2021, including the sale of exclusive rights to the Company’s flavor and fragrance product portfolio to DSM Nutritional Products Ltd.

Other Compensation Elements

Severance Plan

In November 2013, the LDICC adopted the Amyris, Inc. Executive Severance Plan (or the “Severance Plan”). The Severance Plan had an initial term of 36 months and thereafter will be automatically extended for successive additional one-year periods unless we provide six months’ notice of non-renewal prior to the end of the applicable term. As in prior years, in March 2021, the LDICC reviewed the terms of the Severance Plan and elected to allow it to automatically renew. The LDICC adopted the Severance Plan to provide a consistent severance framework for our executive officers that aligns with peer practices. The terms of the Severance Plan, including the potential amounts payable under the Severance Plan and related defined terms, are described in detail below under “Potential Payments upon Termination and upon Termination Following a Change in Control.” All of our NEOs, and all senior level employees of the Company that are eligible to participate in the Severance Plan (or, collectively, the “participants”), have entered into participation agreements to participate in the Severance Plan. Generally, the payments and benefits under the Severance Plan supersede and replace any rights the participants have in connection with any change of control or severance benefits contained in such participants’ employment offer letters, equity award agreements or any other agreement that specifically relates to accelerated vesting of equity awards; provided, that (i) our CEO, CFO and COO are entitled to the rights and benefits provided for in their

 

AMYRIS, INC. 2022 PROXY STATEMENT    53

---

Table of Contents

Executive Compensation  |  Other Compensation Elements

 

respective 2021 Performance Equity Awards in connection with a change of control of the Company, as described above and (ii) in the event of any conflict between the terms of the respective 2021 Performance Equity Awards and the Severance Plan relating to accelerated vesting of equity awards, the terms of each respective 2021 Performance Equity Award will govern and control.

We believe that the Severance Plan appropriately balances our need to offer a competitive level of severance protection to our executive officers and to induce them to remain at the Company through the potentially disruptive conditions that may exist around the time of a change of control of the Company, while not unduly rewarding executive officers for a termination of their employment.

The change in control plan does not provide for the gross-up of any excise taxes imposed by section 4999 of the Internal Revenue Code (the “Code”). If any of the severance benefits payable under the change in control plan would constitute a “parachute payment” within the meaning of section 280G of the Code, subject to the excise tax imposed by section 4999 of the Code, the change in control plan provides for a best after-tax analysis with respect to such payments, under which the executive will receive whichever of the following two alternative forms of payment would result in the executive’s receipt, on an after-tax basis, of the greater amount of the transaction payment notwithstanding that all or some portion of the transaction payment may be subject to the excise tax: (i) payment in full of the entire amount of the transaction payment, or (ii) payment of only a part of the transaction payment so that the executive receives the largest payment possible without the imposition of the excise tax.

Other Executive Benefits and Perquisites

We provide the following benefits to our executive officers on the same basis as other eligible employees:

 

◾

health insurance;

 

◾

time off and sick days;

 

◾

life insurance and supplemental life insurance;

 

◾

short-term and long-term disability; and

 

◾

a Section 401(k) plan with an employer matching contribution (50% match of up to the first 6% of eligible compensation).

We believe that these benefits are generally consistent with those offered by other companies with which we compete for executive talent.

In hiring new executive officers who agree to relocate to Northern California, we have agreed in certain instances to pay relocation and travel expenses, including housing and rental car expenses. Given the high cost of living in the San Francisco Bay Area relative to most other metropolitan areas in the United States, we believe that for us not to be limited to hiring executive officers located near our headquarters in Emeryville, California, we must be willing to offer to pay an agreed upon amount of relocation costs, as necessary.

 

54    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Executive Compensation  |  Additional Compensation Information

 

Additional Compensation Information

Other Compensation Practices and Policies

The following additional compensation practices and policies applied to our executive officers in 2021:

Timing of Equity Awards. The timing of equity awards has been determined by our Board or the LDICC based on our Board’s or the LDICC’s view at the time regarding the adequacy of executive equity interests for purposes of retention and motivation.

As in prior years, in November 2021, our Board and the LDICC, respectively, ratified our existing policy regarding equity award grant dates in an effort to ensure the integrity of the equity award granting process. The original policy was adopted in March 2011. Under the policy, equity awards are generally granted on the following schedule:

 

◾

For equity awards to ongoing executive officers, the grant date is the first business day of the week following the week in which the award is approved; and

 

◾

For equity awards to newly hired executive officers, the grant date is the first business day of the week following the later of the week in which the award is approved or the week in which the new hire commences his or her employment.

Accounting and Tax Considerations

Under ASC 718, the Company is required to estimate the fair value of each equity award (including stock options and RSUs) and record the compensation expense over the underlying vesting period each award. We record share-based compensation expense on an ongoing basis according to ASC 718. The LDICC has considered, and may in the future consider, the grant of performance-based or other types of stock awards to executive officers in lieu of or in addition to stock option and time-based RSU grants in light of the accounting impact of ASC 718 and other considerations.

Generally, Section 162(m) of the Code disallows a federal income tax deduction for public corporations of remuneration in excess of $1 million paid for any fiscal year to their chief executive officer, chief financial officer and up to three other executive officers whose compensation is required to be disclosed to their stockholders under the Exchange Act because they are our most highly-compensated executive officers (“covered employees”). The exemption from Section 162(m)’s deduction limit for “performance-based compensation” has been repealed, effective for taxable years beginning after December 31, 2017, such that compensation paid to our covered employees in excess of $1 million will not be deductible unless it qualifies for transition relief applicable to certain arrangements in place as of November 2, 2017. While the LDICC has not adopted a formal policy regarding tax deductibility of the compensation paid to our executive officers, tax deductibility under Section 162(m) is one factor that is considered in its compensation deliberations.

The LDICC seeks to balance the cost and benefit of tax deductibility with our executive compensation goals that are designed to promote long-term stockholder interest. Therefore, the LDICC may, in its discretion, authorize compensation payments that do not consider the deductibility limit imposed by Section 162(m) when it believes that such payments are appropriate to attract and retain executive talent and are in the best interests of the Company and our stockholders. Accordingly, we expect that a portion of our future cash compensation and equity awards to our executive officers will not be deductible under Section 162(m).

Compensation Recovery Policy. Other than with respect to the CEO PSU Award, CFO PSU Award, and COO PSU Award, as described above, we do not have a formal policy regarding adjustment or recovery of awards or payments if the relevant performance measures upon which they are based are restated or otherwise adjusted in

 

AMYRIS, INC. 2022 PROXY STATEMENT    55

---

Table of Contents

Executive Compensation  |  Additional Compensation Information

 

a manner that would reduce the size of the award or payment. Under those circumstances, our Board or the LDICC would evaluate whether adjustments or recoveries of awards or payments were appropriate based upon the facts and circumstances surrounding the restatement or other adjustment. We anticipate that our Board will adopt a policy regarding restatements in the future based on anticipated SEC and Nasdaq regulations requiring listed companies to have a policy that requires repayment of incentive compensation that was paid to current or former executive officers in the three fiscal years preceding any restatement due to material noncompliance with financial reporting requirements.

Stock Ownership Policy. We have not established stock ownership or similar guidelines with regard to our executive officers. All of our executive officers currently have a direct or indirect, through their stock option holdings, equity interest in the Company and we believe that they regard the potential returns from these interests as a significant element of their potential compensation for services to us.

Insider Trading Policy and Hedging/Pledging Prohibition. We have adopted an Insider Trading Policy that, among other things, prohibits our employees, officers and the non-employee members of our Board from trading in our securities while in possession of material, non-public information. In addition, under our Insider Trading Policy, our employees, officers and the non-employee members of our Board may not (1) engage in transactions involving options or other derivative securities on the Company’s securities, such as puts and calls, whether on an exchange or in any other market (however, they may accept and exercise compensatory equity grants issued by the Company); (2) engage in hedging or monetization transactions involving the Company’s securities; (3) use or pledge Company securities as collateral in a margin account or as collateral for a loan; or (4) engage in short sales of the Company’s securities, including short sales “against the box.”

Leadership, Development, Inclusion, and CompensationCommittee Report*

The LDICC has reviewed and discussed with management the “Compensation Discussion and Analysis” contained in this Proxy Statement. Based on this review and discussion, the LDICC recommended to the Board that the Compensation Discussion and Analysis be included in this Proxy Statement.

Amyris, Inc. Leadership, Development, Inclusion, and Compensation Committee of the Board

James McCann (Chair)

Steven Mills

Ryan Panchadsaram

Julie Spencer Washington

* The material in this report is not “soliciting material,” is not deemed “filed” with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Amyris, Inc. under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

 

56    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Executive Compensation  |  Summary Compensation Table

 

Summary Compensation Table

 

Name and Principal Position		Year				Salary ($)				Bonus ($)				Stock Award ($)(1)				Option Award ($)(1)				Non-Equity Incentive Plan Compensation ($)(2)				All Other Compensation ($)				Total ($)
John Melo, CEO			2021				712,500	(3)			532,650	(4)			70,564,997	(5)			—				696,480				—				72,506,627
			2020				646,667	(3)			—				—				—				698,246				—				1,344,913
			2019				630,000				185,320	(4)			144,424				11,680				333,613	(6)			1,261	(7)			1,306,298
Han Kieftenbeld, CFO			2021				450,000	(8)			182,248	(9)			4,767,250	(10)			—				434,060				8,880	(11)			5,842,438
			2020				332,500				125,000	(12)			745,050				187,104				359,666				675	(11)			1,749,995
Eduardo Alvarez, COO			2021				500,000				164,400	(13)			8,034,000	(14)			—				577,950				1,440	(16)			9,277,790
			2020				500,000				—				579,000				145,555				458,235				1,440	(16)			1,684,320
			2019				416,667	(15)			—				—				—				245,825				2,701	(7)(16)			665,192
Nicole Kelsey, CLO			2021				413,750	(17)			42,778	(18)			669,500				268,075				158,187				8,700	(11)			1,560,990
			2020				395,000				—				115,800				72,778				139,405				7,125	(11)			730,108
			2019				395,000				—				—				—				98,513				5,600	(11)			499,113

(1)

The amounts in the “Stock Awards” and “Option Awards” columns reflect the aggregate grant date fair value of such awards computed in accordance with FASB ASC Topic 718, excluding the effect of estimated forfeitures. A Monte Carlo simulation is used to calculate the fair value of PSUs with service and market-based vesting conditions, as applicable. The assumptions made in the valuation of the awards are discussed in Note 13, “Stock-based Compensation” of “Notes to Consolidated Financial Statements” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. These amounts do not correspond to the actual value that may be recognized by our named executive officers.

(2)	Payments under our 2021 cash bonus plan are included in the column entitled “Non-Equity Incentive Plan Compensation,” as they were based upon the satisfaction of pre-established performance targets, the outcome of which was substantially uncertain.

(3)	Mr. Melo’s annual base salary was increased from $650,000 to $750,000 effective May 16, 2021 and from $630,000 to $650,000 effective March 1, 2020.

(4)

Consists of (a) a $400,000 cash bonus, which was approved by the LDICC in May 2021 to be granted to Mr. Melo in recognition of his extraordinary efforts in negotiating, structuring and consummating certain transformative transactions for the Company in the first quarter of 2021, including the sale of exclusive rights to the Company’s flavor and fragrance product portfolio DSM Nutritional Products Ltd. (the “May 2021 CEO Award”) and (b) the amount approved by the LDICC, in its discretion, which exceeded the applicable funded level for each of the CEO’s quarterly bonus payments in the second, third and fourth quarters of 2021. See “Executive Compensation—Compensation Discussion and Analysis—2021 Compensation—Cash Bonuses” above for more information.

(5)

Consists of (a) an RSU award with a grant date value of $2,000,000 (vesting immediately) pursuant to the May 2021 CEO Award and (b) the CEO PSU Award with a grant date value of $68,565,000, which was approved by our stockholders at a special meeting of stockholders on July 26, 2021. For more information regarding the CEO PSU Award and vesting terms, please see above under “Executive Compensation—Compensation Discussion and Analysis—2021 Compensation—Equity Awards—2021 Performance Equity Awards—CEO PSU Award and CFO PSU Award.”

(6)	In March 2020, the LDICC approved a discretionary increase in the cash bonus to be paid to Mr. Melo for the annual period of 2019, from $74,119 to $95,000, in recognition of his contributions.

(7)	Refers to taxes associated with long term disability insurance.

(8)	Mr. Kieftenbeld was appointed our CFO effective March 16, 2020, and also appointed Chief Administration Officer effective July 1, 2020. His annual base salary for 2020 was $420,000, which was increased from $420,000 to $460,000 effective April 1, 2021.

(9)

Consists of (a) a $100,000 cash bonus, which was approved by the LDICC in May 2021 to be granted to Mr. Kieftenbeld in recognition of his extraordinary efforts in procuring and negotiating a licensing transaction with Ingredion Incorporated (the “May 2021 CFO Award”) and (b) the amount approved by the LDICC, in its discretion, which exceeded the applicable funded level for each of the CFO’s quarterly bonus payments in the second, third and fourth quarters of 2021. See “Executive Compensation—Compensation Discussion and Analysis—2021 Compensation—Cash Bonuses” above for more information.

(10)

Consists of (a) a grant to Mr. Kieftenbeld of 100,000 RSUs, vesting in three equal annual installments pursuant to the May 2021 CFO Award, and (b) the CFO PSU Award. For more information regarding the CFO PSU Award with a grant date value of $3,428,450, please see above under “Executive Compensation—Compensation Discussion and Analysis—2021 Compensation—Equity Awards—2021 Performance Equity Awards—CEO PSU Award and CFO PSU Award.”

(11)	Includes Section 401(k) plan employer matching contribution and gross up for taxes on taxable benefit received.

(12)	In 2020 Mr. Kieftenbeld received a sign-on bonus paid in connection with his appointment as CFO.

(13)	Consists of (a) a $75,000 cash bonus which was approved by the LDICC in May 2021 to be granted to Mr. Alvarez in recognition of his extraordinary efforts in assisting in the negotiation and closing of the transaction with Ingredion Incorporated and (b) the amount approved

 

AMYRIS, INC. 2022 PROXY STATEMENT    57

---

Table of Contents

Executive Compensation  |  Narrative Disclosure to Summary Compensation Table

 

by the LDICC, in its discretion, which exceeded the applicable funded level for each of the COO’s quarterly bonus payments in the second, third and fourth quarters of 2021. See “Executive Compensation—Compensation Discussion and Analysis—2021 Compensation—Cash Bonuses” above for more information.

(14)	Consists of the COO PSU Award. For more information regarding the COO PSU Award, please see above under “Executive Compensation—Compensation Discussion and Analysis—2021 Compensation—Equity Awards—2021 Performance Equity Awards—COO PSU Award.”

(15)	Mr. Alvarez’s base salary was increased from $400,000 to $500,000 effective November 1, 2019.

(16)	Represents a stipend for waiving medical benefits.

(17)	Ms. Kelsey’s base salary was increased from $395,000 to $425,000, effective May 16, 2021.

(18)

Consists of (a) a cash bonus of $5,000 which was approved by the LDICC in December 2021 to be granted to Ms. Kelsey in recognition of her efforts in resolving a government investigation and (b) the amount approved by the LDICC, in its discretion, which exceeded the applicable funded level for each of the CLO’s quarterly bonus payments in the second, third and fourth quarters of 2021. See “Executive Compensation—Compensation Discussion and Analysis—2021 Compensation—Cash Bonuses” above for more information.

Narrative Disclosure to Summary Compensation Table

The material terms of our named executive officers’ annual compensation, including base salaries, cash bonuses, our equity award granting practices and severance benefits and explanations of decisions for cash and equity compensation during 2021 are described above under “Executive Compensation—Compensation Discussion and Analysis.” As noted below under “Agreements with Executive Officers,” except for certain terms contained in their employment offer letters, equity award agreements and participation agreements entered into in connection with our Executive Severance Plan, none of our named executive officers has entered into a written employment agreement with us.

Grants of Plan-Based Awards in 2021

The following table sets forth information regarding grants of compensation in the form of plan- based awards made during 2021 to our named executive officers.

 

						Approval Date of Grant(1)				Estimated Possible Payouts Under Non-Equity  Incentive Plan Awards												All Other Stock Awards: Number of Shares of Stock or Units (#)(3)				All Other Option Awards: Number of Securities Underlying Options (#)(4)				Exercise or Base Price of Option Awards ($/Sh)(5)				Grant Date Fair Value of Stock and Option Awards ($)(6)
Name		Grant Date(1)								Threshold ($)(2)				Target ($)(2)				Maximum ($)(2)
John Melo			—				—				365,000				730,000				1,460,000				—				—				—				—
			5/24/21				5/18/21				—				—				—				149,365	(7)			—				—				1,999,997
			8/2/21				7/26/21				—				—				—				6,000,000	(8)			—				—				68,565,000
Han Kieftenbeld			—				—				223,850				447,700				895,400				—				—				—				—
			5/24/21				5/18/21				—				—				—				100,000	(9)			—				—				1,339,000
			8/2/21				7/26/21				—				—				—				300,000	(8)			—				—				3,428,250
Eduardo Alvarez			—				—				250,000				500,000				1,000,000				—				—				—				—
			5/24/21				5/18/21				—				—				—				600,000	(8)			—				—				8,034,000
Nicole Kelsey			—				—				104,750				209,500				419,000				—				—				—				—
			5/24/21				5/18/21				—				—				—				50,000	(9)			—				—				669,500
			5/24/21				5/18/21				—				—				—				—				25,000	(10)			13.39				268,075

(1)

Our Board has adopted a policy regarding the grant date of equity awards under which the grant date of equity awards generally would be, for awards to ongoing employees, the first business day of the week following the week in which the award was approved by the LDICC or, for new hire awards, the first business day of the week following the later of the week in which the award is approved by the LDICC or the week in which the new hire commences his or her employment. The CEO PSU Award listed in the table above was approved by the LDICC and the Board in May 2021 and approved by our stockholders at our 2021 special meeting of stockholders held on July 26, 2021. Following such stockholder approval and in accordance with our policy regarding equity award grant dates, the CEO PSU Award and CFO PSU awards were granted on August 2, 2021, the first business day of the week following the week in which such awards were approved.

 

58    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Executive Compensation  |  Grants of Plan-Based Awards in 2021

 

(2)

In May 2021, the LDICC approved our 2021 cash bonus plan, a non-equity incentive plan, under which the eligible amounts reported under “Estimated Possible Payouts Under Non-Equity Incentive Plan Awards” were based. The terms of the plan and actual amounts paid out under the plan are discussed above in this Proxy Statement under “Executive Compensation—2021 Compensation—Cash Bonuses” and the amounts paid out under the plan are included in the “Non-Equity Incentive Plan Compensation” column of the “Summary Compensation Table” above. The estimated possible payouts as of December 31, 2021 shown in this table reflect the potential incentive awards that could have been paid for the four quarters and annual period of 2021 at the threshold, target and maximum levels for each individual.

(3)	Amounts in this column represent RSU awards granted under the 2020 EIP.

(4)	Amounts in this column represent stock option awards granted under the 2020 EIP.

(5)	The exercise price per share of the stock options listed in the table above is the closing price of our common stock on Nasdaq on the Grant Date, which represents the fair value of our common stock on the same date. RSU awards do not have any exercise price.

(6)

Reflects the grant date fair value of each award computed in accordance with FASB ASC Topic 718, excluding the effect of estimated forfeitures. The assumptions made in the valuation of the awards are discussed in Note 13, “Stock-based Compensation” of “Notes to Consolidated Financial Statements” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

(7)	These RSUs vested in full on May 31, 2021.

(8)

These RSUs are subject to performance-based vesting conditions subject to continued service through each vesting date. For more information regarding these RSUs, please see above under “Executive Compensation—Compensation Discussion and Analysis—2021 Compensation—Equity Awards—2021 Performance Equity Awards—CEO PSU Award and CFO PSU Award—COO PSU Award.” Such RSUs are also subject to acceleration of vesting upon termination of employment in connection with a change of control, as further described below under “Potential Payments upon Termination and upon Termination Following a Change in Control.”

(9)

These RSUs vest in three equal annual installments, with the first one-third of the units vesting on June 1, 2021, subject to continued service through each vesting date. Such restricted stock units are subject to acceleration of vesting upon termination of employment, as further described below under “Potential Payments upon Termination and upon Termination Following a Change in Control.”

(10)

These stock options have a four-year vesting schedule, with 25% of the shares subject to the stock options vesting on May 24, 2022 with the remainder vesting over the following three years in equal annual installments, subject to continued service through each vesting date. Such stock options are subject to acceleration of vesting upon termination of employment following a change of control, as further described below under “Potential Payments upon Termination and upon Termination Following a Change in Control.”

 

AMYRIS, INC. 2022 PROXY STATEMENT    59

---

Table of Contents

Executive Compensation  |  Outstanding Equity Awards

 

Outstanding Equity Awards

The following table sets forth information regarding outstanding equity awards held by our named executive officers as of December 31, 2021.

 

		Option Awards																				Stock Awards
Name		Number of Securities Underlying Unexercised Options (#) Exercisable					Number of Securities Underlying Unexercised Options (#)(1) Unexercisable					Option Exercise Price ($/Sh)					Option Expiration Date					Number of Shares or Units of Stock That Have Not Vested  (#)					Market Value of Shares or Units of Stock That Have Not Vested ($)(2)
John Melo				6,666					—					57.90					4/9/2022					—					—
				24,066					—					43.05					6/3/2023					—					—
				20,000					—					52.65					5/5/2024					—					—
				28,333					—					29.40					6/8/2025					—					—
				6,000					—					24.45					11/9/2025					—					—
				28,333					—					8.85					5/16/2026					—					—
				20,000					—					3.16					6/12/2027					—					—
				4,161					—					3.74					1/14/2029
				—					—					—					—					175,000	(3)				946,750
				—					—					—					—					6,000,000	(4)				32,460,000
Han Kieftenbeld				11,953					10,547	(5)				2.46					3/30/2030					33,750	(6)				182,588
				15,625					34,375	(7)				3.86					8/10/2030					100,000	(8)				541,000
				—					—					—					—					100,000	(9)				541,000
				—					—					—					—					300,000	(4)				1,623,000
Eduardo Alvarez				30,000					—					2.89					10/23/2027					—					—
				15,625					34,375	(7)				3.86					8/10/2030					100,000	(8)				541,000
				—					—					—					—					600,000	(4)				3,246,000
Nicole Kelsey				9,000					—					2.49					8/14/2027					—					—
				44,791					5,209	(10)				5.08					5/29/2028					—					—
				7.812					17,188	(7)				3.86					8/10/2030					20,000	(8)				108,200
				—					25,000	(11)				13.39					5/24/2031					50,000	(9)				270,500

(1)

In addition to the specific vesting schedule for each award, each unvested award is subject to the general terms of the 2010 EIP or 2020 EIP, as applicable, including the potential for future vesting acceleration of vesting upon termination of employment in connection with a change of control, as further described below under “Potential Payments upon Termination and upon Termination Following a Change in Control.”

(2)	The market values of the RSU awards that have not vested are calculated by multiplying the number of shares underlying the RSU awards shown in the table by $5.41, the closing price of our ordinary shares on December 31, 2021.

(3)	RSUs awarded on March 30, 2020 vest in equal annual installments over four years with the first installment vesting on July 1, 2019.

(4)

These RSUs are subject to performance-based vesting conditions subject to continued service through each vesting date. For more information regarding these RSUs, please see above under “Executive Compensation—Compensation Discussion and Analysis—2021 Compensation—Equity Awards—2021 Performance Equity Awards—CEO PSU Award and CFO PSU Award” and “COO PSU Award.” Such RSUs are also subject to acceleration of vesting upon termination of employment in connection with a change of control, as further described below under “Potential Payments upon Termination and upon Termination Following a Change in Control.”

(5)	The unexercisable shares subject to this stock option award as of December 31, 2021 will vest monthly from January 1, 2022 to March 16, 2023.

(6)	RSUs awarded on March 30, 2020 vest in equal annual installments over two years with the first installment vesting on June 1, 2021.

(7)	The unexercisable shares subject to this stock option award as of December 31, 2021 will vest monthly from January 1, 2022 to September 1, 2024.

(8)	RSUs awarded on August 10, 2020 vest in equal annual installments over three years with the first installment vesting on September 1, 2021.

 

60    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Executive Compensation  |  Option Exercises and Stock Vested During 2021

 

(9)	RSUs awarded on May 24, 2021 vest in equal annual installments over three years with the first installment vesting on June 1, 2022.

(10)	The unexercisable shares subject to this stock option award as of December 31, 2021 will vest monthly from January 1, 2021 to May 1, 2022.

(11)	The unexercisable shares subject to this stock option award as of December 31, 2021 will vest as to 25% of the shares on May  24, 2022, with the remainder vesting in equal monthly installments over the following three years.

Option Exercises and Stock Vested During 2021

The following table sets forth information regarding the exercise of options and vesting of RSUs held by our named executive officers during 2021.

 

		Option Awards										Stock Awards
Name		Number of Shares Acquired on Exercise (#)					Value Realized on Exercise ($)					Number of Shares Acquired on Vesting (#)					Value Realized on   Vesting ($)(1)
John Melo				—					—					324,365					5,098,714
Han Kieftenbeld				—					—					83,750					1,234,063
Eduardo Alvarez				—					—					50,000					743,000
Nicole Kelsey				—					—					43,333					633,929

(1)	Value realized on vesting is calculated by multiplying the number of units vesting by the closing price of our common stock on Nasdaq on the date of vesting (or most recent closing price in the event the date of vesting falls on a non-trading day).

Pension Benefits

None of our named executive officers participates in, or has an account balance in, a qualified or non-qualified defined benefit plan sponsored by us.

Non-Qualified Deferred Compensation

None of our named executive officers participates in, or has account balances in, a traditional non-qualified deferred compensation plan or any other deferred compensation plan maintained by us.

Potential Payments upon Termination and upon Termination Following a Change in Control

In November 2013, the LDICC adopted the Amyris, Inc. Executive Severance Plan (or the “Severance Plan”). The Severance Plan had an initial term of 36 months and thereafter will be automatically extended for successive additional one-year periods unless we provide six months’ notice of non-renewal prior to the end of the applicable term. As in prior years, in March 2021 the LDICC reviewed the terms of the Severance Plan and elected to allow it to automatically renew. The LDICC adopted the Severance Plan to provide a consistent and updated severance framework for our executive officers that aligns with peer practices. The terms of the Severance Plan, including the potential amounts payable under the Severance Plan and related defined terms, are described in detail below under “Potential Payments upon Termination and upon Termination Following a Change in Control.” All of our named executive officers, and all senior level employees of Amyris that are eligible to participate in the Severance Plan (or, collectively, the “participants”), have entered into participation agreements under the Severance Plan. Generally, the payments and benefits under the Severance Plan supersede and replace any rights the participants have in connection with any change of control or severance benefits contained in such participants’ employment offer letters, equity award agreements or any other agreement that specifically relates to accelerated vesting of equity awards; provided, that (i) our CEO, CFO and COO are entitled to the rights and benefits provided for in their respective 2021 Performance Equity Awards in connection with a change of control of Amyris, as described above and (ii) in the event of any conflict between the terms of the respective 2021 Performance Equity Awards and the

 

AMYRIS, INC. 2022 PROXY STATEMENT    61

---

Table of Contents

Executive Compensation  |  Potential Payments upon Termination and upon Termination Following a Change in Control

 

Severance Plan relating to accelerated vesting of equity awards, the terms of each respective 2021 Performance Equity Award would govern and control.

Upon the execution of a participation agreement, the participants are eligible for the following payments and benefits under the Severance Plan.

Upon termination by us of a participant’s employment other than for “cause” (as defined below) or the death or disability of the participant, or upon resignation by the participant of such participant’s employment for “good reason” (as defined below) (collectively referred to as an “Involuntary Termination”), the participant becomes eligible for the following severance benefits:

 

◾

12 months of base salary continuation (18 months for our CEO)

 

◾

12 months of health benefits continuation (18 months for our CEO)

Upon an Involuntary Termination of a participant at any time within the period beginning three months before and ending 12 months after a change of control (as defined below) of the Company, the participant becomes eligible for the following severance payments and benefits:

 

◾

18 months of base salary continuation (24 months for our CEO)

 

◾

18 months of health benefits continuation (including for our CEO)

 

◾

Automatic acceleration of vesting and exercisability of all outstanding equity awards then held by the participant

In each case, the payments and benefits are contingent upon the participant complying with various requirements, including non-solicitation and confidentiality obligations to us, and on execution, delivery and non-revocation by the participant of a standard release of claims in favor of the Company within 60 days of the participant’s separation from service (as defined in Section 409A of the Code). The payments and benefits are subject to forfeiture if, among other things, the participant breaches any of his or her obligations under the Severance Plan and related agreements. The payments and benefits are also subject to adjustment and deferral based on applicable tax rules relating to change-in-control payments and deferred compensation.

Under the Severance Plan, “cause” generally encompasses the participant’s: (i) gross negligence or intentional misconduct; (ii) failure or inability to satisfactorily perform any assigned duties; (iii) commission of any act of fraud or misappropriation of property or material dishonesty; (iv) conviction of a felony or a crime involving moral turpitude; (v) unauthorized use or disclosure of the confidential information or trade secrets of Amyris or any of our affiliates that use causes material harm to Amyris; (vi) material breach of contractual obligations or policies; (vii) failure to cooperate in good faith with investigations; or (viii) failure to comply with confidentiality or intellectual property agreements. Prior to any determination that “cause” under the Severance Plan has occurred, we are generally required to provide notice to the participant specifying the event or actions giving rise to such determination and a 10-day cure period (30 days in the case of failure or inability to satisfactorily perform any assigned duties).

Under the Severance Plan, “good reason” generally means: (i) a material reduction of the participant’s role at Amyris; (ii) certain reductions of base salary; (iii) a workplace relocation of more than 50 miles; or (iv) our failure to obtain the assumption of the Severance Plan by a successor. In order for a participant to assert good reason for his or her resignation, he or she must provide us written notice within 90 days of the occurrence of the condition and allow us 30 days to cure the condition. Additionally, if we fail to cure the condition within the cure period, the participant must terminate employment with us within 30 days of the end of the cure period.

Under the Severance Plan, a “change of control” will generally be deemed to occur if (i) Amyris completes a merger or consolidation after which Amyris’s stockholders before the merger or consolidation do not own at least a majority of the outstanding voting securities of the acquiring or surviving entity after such merger or consolidation, (ii) Amyris

 

62    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Executive Compensation  |  Potential Payments upon Termination and upon Termination Following a Change in Control

 

sells all or substantially all of its assets, (iii) any person or entity acquires more than 50% of Amyris’s outstanding voting securities or (iv) a majority of Amyris’s directors cease to be directors over any one-year period.

To the extent any severance benefits to a named executive officer constitute deferred compensation subject to Section 409A of the Code and such officer is deemed a “specified employee” under Section 409A, we will defer payment of such benefits to the extent necessary to avoid adverse tax treatment.

For a description of the treatment of the CEO PSU Award, CFO PSU Award and COO PSU Award upon change of control and/or subsequent protected termination, please see “Executive Compensation—Compensation Discussion and Analysis—2021 Compensation—Equity Awards.”

The following table summarizes the potential amounts payable to each of our named executive officers under the Severance Plan upon an Involuntary Termination (i) other than in connection with a change of control of the company and (ii) in connection with a change of control of the company, assuming in each case, that such Involuntary Termination occurred on December 31, 2021.

 

		Involuntary Termination Not in Connection with a Change of Control															Involuntary Termination in Connection with a Change of Control
Name		Base Salary ($)					Continuing Health Benefits ($)					Value of Accelerated Options or Shares ($)(1)					Base Salary ($)					Continuing Health Benefits ($)					Value of Accelerated Options or Shares ($)(2)
John Melo				1,125,000					53,235					—					1,500,000					53,235					946,750
Han Kieftenbeld				460,000					25,149					—					690,000					37,723					1,348,982
Eduardo Alvarez(3)				500,000					—					—					750,000					—					3,840,281
Nicole Kelsey				425,000					20,681					—					637,500					31,021					407,060

(1)	Accelerated vesting is only applicable in the event of an Involuntary Termination in connection with a change of control.

(2)

With respect to outstanding options as of December 31, 2021, calculated by multiplying the number of shares underlying unvested stock options that would vest as a result of an Involuntary Termination following a change of control by the excess of $5.41, the closing price of our common stock on Nasdaq on December 31, 2021, over the exercise price of the stock options. Unvested stock options with exercise prices higher than $5.41 are excluded from the calculation. With respect to outstanding restricted stock units as of December 31, 2021, calculated by multiplying the number of outstanding unvested restricted stock units that would vest as a result of an Involuntary Termination following a change of control by $5.41, the closing price of our common stock on Nasdaq on December 31, 2021. Assumes that the per share price common stock price received by the shareholders in the change of control is measured to be below all Stock Price Milestones of the CEO PSU Award and the CFO PSU Award. For a complete discussion on how the CEO PSU Award and the CFO PSU Award are treated upon a change of control, see “Executive Compensation—Compensation Discussion and Analysis—2021 Compensation—Equity Awards—2021 Performance Equity Awards—CEO PSU Award and CFO PSU Award.”

(3)

Mr. Alvarez’s COO PSU Award agreement provides that if the Company experiences a change of control during the COO Performance Period, the COO Performance Metric for any COO Tranche that has not yet been achieved will be deemed achieved effective as of immediately prior to the closing of the change of control. The resulting “achieved” PSUs (the “COO COC RSUs”) will be unvested on the closing date and will vest on December 31, 2022, subject to Mr. Alvarez’s continuous Service on the closing date and on such vesting date, with such COO COC RSUs accelerating in full upon a termination without cause or resignation of good reason, as provided in the Severance Plan. For a complete discussion on how the COO PSU Award is treated upon a change of control, see ““Executive Compensation—Compensation Discussion and Analysis—2021 Compensation—Equity Awards—2021 Performance Equity Awards—COO PSU Award.”

Pay Ratio Disclosure

Under SEC rules, we are required to calculate and disclose the median of the annual total compensation of all our employees (other than our CEO), the annual total compensation of our CEO and the ratio of the median of the annual total compensation of all our employees compared to the annual total compensation of our CEO, Mr. Melo (our “CEO pay ratio”).

For 2021:

 

◾

The median of the annual total compensation of all our employees (other than our CEO) was $117,489; and

 

AMYRIS, INC. 2022 PROXY STATEMENT    63

---

Table of Contents

Executive Compensation  |  Agreements with Executive Officers

 

◾

the annual total compensation of Mr. Melo, as reported in the “2021 Summary Compensation Table” above, was $72,506,627.

Thus, for 2021, the ratio of our CEO’s annual total compensation to the median of the annual total compensation of all our employees was approximately 617 to 1. This ratio is a reasonable estimate calculated in a manner consistent with Item 402(u) of Regulation S-K.

In determining the median of the annual total compensation of all employees of the Company (other than Mr. Melo), we prepared a list of all employees as of December 31, 2021. We then calculated the annual compensation (base salary, actual and target bonus, and grant date value of equity awards) of our employees as of that date for the 12-month period from January 1, 2021 through December 31, 2021. We did not include any contractors or other non-employee workers in our employee population or any employees of our subsidiaries acquired in M&A transactions during calendar year 2021 (approximately 55 employees). Salaries and wages were annualized for permanent employees who were not employed for the full year of 2021. We used exchange rates in effect as of December 31, 2021 to convert the base salaries and other compensation amounts of our non-U.S. employees to U.S. dollars. We did not make any cost-of-living adjustments.

Using this approach, we selected the individual at the median of our employee population. We then calculated the annual total compensation for this individual using the same methodology we use for our NEOs as set forth in the “2021 Summary Compensation Table” above. Our CEO’s 2021 compensation included (i) a one-time $400,000 cash bonus and one-time RSU award with a grant date value of $2 million (vesting immediately), in each case recognizing Mr. Melo’s extraordinary efforts in negotiating, structuring and consummating certain transformative transactions for the Company in the first quarter of 2021, and (ii) the CEO PSU Award with a grant date fair value of $68.6 million. For more information regarding the CEO compensation, please see above under “Executive Compensation—Compensation Discussion and Analysis—2021 Compensation”.

We are providing a supplemental ratio that compares Mr. Melo’s total 2021 compensation, excluding the CEO PSU Award, with a grant date fair value of $68.6 million (see “Executive Compensation—Compensation Discussion and Analysis—2021 Compensation—Equity Awards—2021 Performance Equity Awards—CEO PSU Award and CFO PSU Award” above for additional information), to the annual total compensation of the median employee to facilitate a better understanding of our CEO’s ongoing annual total compensation and better comparability. The resulting supplemental CEO pay ratio is approximately 34 to 1.

Agreements with Executive Officers

We do not have formal employment agreements with any of our named executive officers. The initial compensation of each named executive officer was set forth in an employment offer or promotion letter that we executed with such executive officer at the time his or her employment with us commenced (or at the time of her or his promotion, as the case may be). Each employment offer letter provides that the named executive officer’s employment is “at will.”

As a condition to their employment, our named executive officers entered into non-competition, non-solicitation and proprietary information and inventions assignment agreements. Under these agreements, each named executive officer has agreed (i) not to solicit our employees during her or his employment and for a period of 12 months after the termination of his or her employment, (ii) not to compete with us or assist any other person to compete with us during her or his employment, and (iii) to protect our confidential and proprietary information and to assign to us intellectual property developed during the course of his or her employment.

See above under “Executive Compensation—Potential Payments upon Termination and upon Termination Following a Change in Control” for a description of potential payments to our named executive officers upon termination of employment, including in connection with a change of control of the Company.

 

64    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

		Director Compensation

 

Director Compensation for 2021

During the fiscal year ended December 31, 2021, our non-employee directors who served during 2021 earned the compensation set forth below.

 

Name		Fees Earned or Paid in Cash ($)(1)					Stock Awards ($)(2)(11)					Option Awards($)(2)(11)					All Other Director Compensation ($)					Total ($)
John Doerr(3)				14,750					232,515					—					—					247,265
Geoffrey Duyk				51,181					107,060					—					—					158,241
Philip Eykerman(4)				43,681					107,060					—					—					150,741
Christoph Goppelsroeder(5)				10,000					—					—					—					10,000
Frank Kung(6)				43,681					107,060					—					—					150,741
James McCann				54,863					107,060					—					—					161,923
Steven Mills				75,368					107,060					—					—					182,428
Ryan Panchadsaram(7)				24,354					107,060					—					—					131,414
Carole Piwnica(8)				22,254					—					—					—					22,254
Lisa Qi(9)				45,338					146,884					48,238					—					240,460
Julie Spencer Washington				49,049					107,060					—					—					156,109
Patrick Yang(10)				30,434					—					—					—					30,434

(1)	Reflects Board, Committee Chair and Committee member retainer fees earned during 2021.

(2)

The amounts in the “Stock Awards” and “Option Awards” columns reflect the aggregate grant date fair value of such awards computed in accordance with FASB ASC Topic 718. The assumptions made in the valuation of the awards are discussed in Note 13, “Stock-based Compensation” of “Notes to Consolidated Financial Statements” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. These amounts do not correspond to the actual value that may be recognized by our non-employee directors. In August 2021, each of our then non-employee directors received an annual award under the 2020 EIP of 7,409 RSUs in accordance with our non-employee director compensation program described below.

(3)

In August 2021, the LDICC approved the payment of Mr. Doerr’s annual cash retainers from January 2019 through September 2021, which were previously irrevocably waived in full by him, in the form of RSUs vesting on September 30, 2021 and calculated based on the 30-day VWAP of our common stock as of July 31, 2021. The grant date fair value for this award of 8,682 RSUs, as calculated under FASB ASC Topic 718, is $125,455.

(4)	All cash compensation earned by Mr. Eykerman during 2021 was to be paid directly to DSM, which designated Mr. Eykerman to serve on our Board, and he did not receive any cash benefit from such payments.

(5)

Mr. Goppelsroeder resigned from the Board as of April 1, 2021. All cash compensation earned by him during 2021 was to be paid directly to DSM, which designated Mr. Goppelsroeder to serve on our Board, and he did not receive any cash benefit from such payments. In addition, Mr. Goppelsroeder declined each equity award granted to him pursuant to our non-employee director compensation program.

(6)

All cash compensation earned by Dr. Kung during 2021 was to be paid directly to Vivo, which designated Dr. Kung to serve on our Board, and Dr. Kung did not receive any cash benefit from such payments. Pursuant to an agreement between Dr. Kung and Vivo, Dr. Kung has agreed, subject to certain conditions and exceptions, to remit the equity compensation he receives under our non-employee director compensation program to Vivo if and when such equity compensation becomes vested and/or exercised.

(7)	Mr. Panchadsaram was appointed to our Board in August 2021 and the fees earned by him in 2021 represent retainer fees earned for the portions of 2021 that he served on our Board.

(8)	Ms. Piwnica resigned from the Board as of May 28, 2021.

(9)

In August 2021, the LDICC approved the issuance to Ms. Qi of her initial equity awards in 2019 and her 2020 annual equity awards which were previously irrevocably waived in full by her. Ms. Qi received an award under the 2020 EIP of an option to purchase 4,216 shares of our common stock and 2,756 RSUs. This award was contemplated by our non-employee director compensation program in effect during

 

AMYRIS, INC. 2022 PROXY STATEMENT    65

---

Table of Contents

Director Compensation  |  Narrative Disclosure to Director Compensation Tables

 

2019 and 2020 (described in “Narrative Disclosure to Director Compensation Tables” below). The stock option and RSU awards vested in full on September 30, 2021. The grant date fair value for these awards, as calculated under FASB ASC Topic 718, is as follows:

 

Name		Date of Grant					Number of Shares of Stock or Units (#)					Number of Securities Underlying Options (#)					Exercise Price Per Share ($)					Stock Awards ($)(2)					Option Awards ($)(2)
Lisa Qi				8/23/2021					—					4,216					14.45					—					48,238
Lisa Qi				8/23/2021					2,756					—					—					39,824					—

 

(10)	Mr. Yang resigned from the Board as of September 1, 2021.

(11)	As of December 31, 2021, the non-employee directors who served during 2021 held the following outstanding equity awards:

 

Name		Outstanding Options (Shares)					Outstanding Stock Awards (Units)
John Doerr				15,464					7,409
Geoffrey Duyk				11,598					7,409
Philip Eykerman				15,131					7,409
Christoph Goppelsroeder				—					—
Frank Kung				13,398					7,409
James McCann				7,682					7,409
Steven Mills				10,398					7,409
Ryan Panchadsaram				—					7,409
Carole Piwnica				—					—
Lisa Qi				4,216					7,409
Julie Spencer Washington				3,466					7,409
Patrick Yang				—					—

Narrative Disclosure to Director Compensation Tables

Under our current non-employee director compensation program, as amended by the Board and effective in August 2021, and in each case subject to final approval by our Board with respect to equity awards:

 

◾

Each non-employee director receives an annual cash retainer of $50,000 and an annual equity award of RSUs with a value of $115,000, vesting in full after one year (in each case subject to continued service through the applicable vesting date). Any new Board members will receive a pro-rated annual equity award upon joining our Board, which award will vest in full on the one-year anniversary of the grant of the most recent annual Board equity awards.

 

◾

The Chair of the Audit Committee receives an additional annual cash retainer of $20,000.

 

◾

The Chair of the LDICC receives an additional annual cash retainer of $13,000.

 

◾

The Chair of the NGC receives an additional annual cash retainer of $9,000.

 

◾

Audit Committee, LDICC and NGC members other than the Chair receive an additional annual cash retainer of $7,500, $6,000 and $4,500, respectively.

In general, all the retainers described above are paid quarterly in arrears. Starting in fiscal year 2022, directors may elect to receive RSUs in lieu of their cash retainers (“retainer RSUs”). Directors must make this election annually and such election is binding on the full amount of the retainer for the applicable four-quarter period. In cases where a non-employee director serves for part of the year in a capacity entitling him or her to a retainer payment,

 

66    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Director Compensation  |  Compensation Committee Interlocks and Insider Participation

 

the retainer is prorated to reflect his or her period of service in that capacity and unvested retainer RSUs are cancelled upon a director departure. Non-employee directors are also eligible for reimbursement of their expenses incurred in attending Board and Committee meetings.

Pursuant to our 2020 Equity Incentive Plan, a non-employee director may receive compensation (including cash and equity awards) representing no more than $500,000 total value in any calendar year.

Compensation Committee Interlocks and Insider Participation

None of the members of our LDICC was at any time our officer or employee during 2021. None of our executive officers serve, or in the past fiscal year served, as a member of the board of directors or the compensation committee of any entity that has one or more of its executive officers serving on our Board or LDICC.

 

AMYRIS, INC. 2022 PROXY STATEMENT    67

---

Table of Contents

		Transactions with Related Persons

 

Certain Transactions

The following is a description of each transaction since the beginning of 2021, and each currently proposed transaction, in which:

 

◾

we have been or are to be a participant;

 

◾

the amount involved exceeds the lesser of $120,000; and

 

◾

any of our directors, executive officers or holders of more than 5% of any class of our capital stock at the time of the transactions in issue, or any immediate family member of or person sharing the household with any of these individuals, had or will have a direct or indirect material interest.

Transactions with Foris

Loan and Security Agreement Amendment. On November 9, 2021, the Company, certain of the Company’s subsidiaries (the “Subsidiary Guarantors”) and Foris Ventures, LLC (“Foris”), an entity affiliated with director John Doerr, a current stockholder and beneficial owner of greater than five percent of our outstanding common stock, and director Ryan Panchadsaram, entered into Amendment No. 2 to the Amended and Restated Loan and Security Agreement, dated October 28, 2019 (as amended, the “LSA”), by and among the Company, the Subsidiary Guarantors and Foris, under which approximately $50.0 million was outstanding as of December 31, 2021, pursuant to which, among other things, (i) the definition of permitted indebtedness under the LSA was amended to permit the issuance of certain senior convertible notes due 2026 issued on November 15, 2021 (the “Convertible Notes”); and (ii) the definitions of permitted investment and permitted transfer under the LSA were amended to permit certain capped call transactions in connection with the issuance of the Convertible Notes.

Credit Agreement Repayment and Termination. On November 15, 2021, with proceeds from the Convertible Notes offering, the Company paid Foris an aggregate of $5.9 million representing all principal and interest due under the Credit Agreement dated as of April 29, 2020, by and between the Company and Foris, thereby terminating such agreement.

Warrants Exercises. On July 31, 2021, the Company and Foris entered into an Exercise Notice and Agreement with respect to a right to purchase shares of the Company’s common stock issued to Foris by the Company on January 31, 2020, as amended, whereby Foris exercised the right to purchase 3,778,230 shares of the Company’s common stock at an exercise price of $2.87 per share and the Company agreed to receive the exercise price payment and issue the corresponding shares once Foris obtained clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 as amended, which was obtained on September 7, 2021. On September 9, 2021, the Company received approximately $10.8 million representing the exercise price and issued 3,778,230 shares of its Company’s common stock to Foris.

Transactions with DSM

Performance Agreement. On December 28, 2017, the Company and DSM Nutritional Products AG (together with its affiliates, “DSM”), a commercial partner and affiliate of an owner of greater than five percent of the Company’s outstanding common stock, which has the right to designate up to two members of our Board of Directors, entered into a Performance Agreement (as amended, the “Performance Agreement”) pursuant to which the Company provides certain research and development services to DSM relating to the development of the

 

68    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Transactions with Related Persons  |  Certain Transactions

 

technology underlying the farnesene-related products in exchange for related funding, including certain bonus payments in the event that specific performance metrics are achieved. If the Company did not meet the established metrics under the Performance Agreement, the Company would be required to pay $1.9 million to DSM. In the first quarter of 2021, the Company and DSM determined the performance metrics would not be reasonably achieved without the Company providing further research and development services and concluded the Performance Agreement and related activities should be terminated and, as a result, the Company paid DSM $1.9 million in 2021.

Asset Purchase Agreement and License Agreement. On March 31, 2021, the Company and DSM entered into (i) an Asset Purchase Agreement pursuant to which DSM acquired exclusive rights to the Company’s Flavor and Fragrance (“F&F”) product portfolio except for the intellectual property related to the F&F business, (ii) a License and Drawing Rights Agreement pursuant to which the Company granted DSM an exclusive, perpetual, royalty-free, world-wide, and irrevocable license covering the F&F business intellectual property, and (iii) a Supply Agreement, pursuant to which the Company will manufacture certain F&F ingredients to DSM for a 15-year term, in exchange for non-refundable upfront consideration totaling $150.0 million and up to $235.0 million of contingent consideration if and when certain commercial milestones are achieved in each of the calendar years 2022 through 2024. DSM also acquired the Company’s F&F finished goods inventory on-hand, unbilled accounts receivables and billed accounts receivable that were uncollected at closing. Effective November 10, 2021, the Company and DSM amended the Supply Agreement to temporarily reduce the manufacturing fee of certain molecules as an incentive to stimulate more rapid adoption of such products by the market.

Developer License Agreement. In September 2021, the Company granted DSM a three-year license to perform research and development to improve and enhance certain technology underlying the Company’s farnesene-related yeast strain in exchange for a $6.0 million license fee.

Credit Agreement Repayment and Termination. On March 1, 2021 and March 31, 2021, the Company and DSM entered into certain amendments to (a) the $25 million note issued by the Company to DSM on December 28, 2017, maturing on December 31, 2021 and accruing interest at 10% per annum (the “2017 Note”) and (b) the $8 million aggregate notes issued by the Company to DSM on September 17, 2019, September 19, 2019, and September 23, 2019 maturing on August 7, 2022, accruing interest at 12.5% per annum, and secured by a first-priority lien on certain Company intellectual property licensed to DSM (collectively, the “2019 Notes”). Such amendments provided for, (i) the prepayment of the 2019 Notes, (ii) the partial $15 million prepayment of the 2017 Note, and (iii) extension of the maturity date of the 2017 Note from December 31, 2021 to April 15, 2022 with respect to its remaining $10 million principal balance, in exchange for a $2.5 million prepayment fee. On March 31, 2021, the Company paid $23 million to DSM in full repayment of the 2019 Notes and partial repayment of the 2017 Note. On November 15, 2021, with proceeds from the Convertible Notes offering, the Company paid DSM an aggregate of $10.1 million representing all remaining principal and interest due under the 2019 Notes.

Warrant Exercises. On January 19, 2021, DSM provided to the Company notices of cashless exercise to purchase an aggregate 7,936,232 shares of the Company’s common stock at an exercise price of $2.87 per share, pursuant to certain cashless common stock purchase warrants issued by the Company on May 11, 2017 and August 7, 2017 and, in connection therewith the Company issued to DSM a total of 6,056,944 shares of its common stock.

On April 8, 2021, DSM provided to the Company notices of cash exercise to purchase an aggregate 6,057,966 shares of the Company’s common stock at an exercise price of $2.87 per share, pursuant to certain anti-dilution common stock purchase warrants issued by the Company on May 11, 2017 and August 7, 2017 and, in connection therewith the Company received approximately $5 thousand.

 

AMYRIS, INC. 2022 PROXY STATEMENT    69

---

Table of Contents

Transactions with Related Persons  |  Certain Transactions

 

Secondary Offering. On April 8, 2021, the Company entered into an underwriting agreement with J.P. Morgan Securities LLC and Cowen and Company, LLC, as underwriters, and with DSM and Vivo (as defined below), as selling stockholders, pursuant to which, among other things, DSM agreed to sell an 7,322,655 shares of the Company’s common stock and granted the underwriters a 30-day option to purchase up to an additional 1,098,398 shares of common stock from the selling stockholders, which was exercised in full. The Company did not receive any proceeds from the sale of common stock in the secondary offering by the selling stockholders.

Transactions with Vivo

Warrants Exercises. On April 6, 2021, affiliates of Vivo Capital LLC (collectively, “Vivo”), an entity affiliated with the Company’s director Frank Kung and which owned greater than five percent of the Company’s outstanding common stock during 2021 and has the right to designate one member of the Company’s Board of Directors, provided to the Company notices of cash exercise to purchase an aggregate 1,212,787 shares of the Company’s common stock at an exercise price of $2.87 per share, pursuant to certain Common Stock Purchase Warrants issued by the Company on April 29, 2019 and, in connection therewith the Company received approximately $5.8 million representing the exercise payment from Vivo.

Secondary Offering. On April 8, 2021, the Company entered into an underwriting agreement with J.P. Morgan Securities LLC and Cowen and Company, LLC, as underwriters, and with DSM and Vivo, as selling stockholders, pursuant to which, among other things, Vivo agreed to sell an aggregate 4,068,142 shares of the Company’s common stock and granted the underwriters a 30-day option to purchase up to an additional 610,221 shares of common stock from the selling stockholders, which was exercised in full. The Company did not receive any proceeds from the sale of common stock in the secondary offering by the selling stockholders.

Warrant Exercises by Fidelity

On January 7, 2021, affiliates of FMR LLC (“Fidelity”), an entity which then owned greater than five percent of our outstanding common stock, provided to the Company notices of cash exercise to purchase an aggregate 2,782,258 shares of the Company’s common stock at an exercise price of $2.87 per share, pursuant to certain Common Stock Purchase Rights issued by the Company to Fidelity on January 31, 2020 and, in connection therewith, the Company received $10.0  million representing the exercise payment from Fidelity.

Compensation Arrangements

Stephanie Kung, the daughter of director Frank Kung, is a non-executive employee of the Company and received employment compensation plus benefits in excess of $120,000 in 2021, and she is expected to receive employment compensation plus benefits in excess of $120,000 in 2022.

On October 4, 2021, Sofia Melo, the daughter of John Melo, the Company’s President and Chief Executive Officer and a member of the Board, was hired as an executive producer reporting to the Company’s Chief Brand Activist, with total annual target cash and equity compensation plus benefits in excess of $120,000.

Indemnification Arrangements

We have entered into indemnification agreements with each of our directors and executive officers that may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements require us, among other things, to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all expenses incurred by the directors and executive officers in investigating or defending against any such action, suit or proceeding. We believe that these agreements are necessary to attract and retain qualified

 

70    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Transactions with Related Persons  |  Related Party Transactions Policy

 

individuals to serve as directors and executive officers. We maintain an insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers. Certain of our non-employee directors may, through their relationships with their employers, be insured and/or indemnified against certain liabilities incurred in their capacity as members of the Board.

Executive Compensation and Employment Arrangements

Please see “Executive Compensation” above for information regarding our compensation arrangements with our executive officers, including equity awards and employment agreements with our executive officers.

Registration Rights Agreements

Certain of our stockholders, including certain entities affiliated with our directors and/or holders of five percent or more of our outstanding common stock hold registration rights pursuant to the following:

 

◾

Letter agreement, dated July 29, 2015, by and among us and certain investors

 

◾

Securities Purchase Agreement, dated May 8, 2017, by and among us and certain investors

 

◾

Securities Purchase Agreement, dated August 2, 2017, by and between us and DSM International B.V.

 

◾

Stockholder Agreement, dated August 3, 2017, by and between us and affiliates of Vivo Capital LLC

 

◾

Amended and Restated Stockholder Agreement, dated August 7, 2017, by and between us and DSM International B.V.

 

◾

Securities Purchase Agreements, dated January 31, 2020, by and between us and the investor named therein, including Foris Ventures, LLC.

 

◾

Security Purchase Agreements, dated June 1, 2020 and June 4, 2020, by and between us and the investors named therein, including Foris Ventures, LLC, and Vivo Capital LLC.

 

◾

Securities Purchase Agreement, dated May 7, 2021, with Upland1,LLC and the other parties thereto.

 

◾

Share Purchase Agreement, dated August 11, 2021, with MG Empower Ltd. and the other parties thereto.

 

◾

Agreement and Plan of Merger and Reorganization and Note Purchase Agreement, each dated August 11, 2021, by and among the Company, OLIKA Inc. and the other parties thereto.

 

◾

Share Purchase Agreement and Option Cancellation Agreements, each dated as of August 31, 2021, by and among the Company, Beauty Labs International Limited and the selling stockholders party thereto.

 

◾

Agreement and Plan of Merger dated January 26, 2022, by and among the Company, certain of its subsidiaries, No Planet B Holdings, Inc. and its stockholders.

 

◾

Asset Purchase Agreement dated March 9, 2022, by and among the Company, certain of its subsidiaries, and MenoLabs, LLC.

Related Party Transactions Policy

Our Related Party Transactions Policy adopted by our Board of Directors requires that any transaction with a related party that must be reported under applicable SEC rules, other than certain compensation related matters, must be reviewed and approved or ratified by the Audit Committee of our Board of Directors. Our Related Party Transactions Policy contains specific procedures to be followed, and factors to be considered, in connection with the review of such transactions, but does not contain specific standards for approval of such transactions.

 

AMYRIS, INC. 2022 PROXY STATEMENT    71

---

Table of Contents

		Annual Meeting Information

 

Information Regarding Solicitation and Voting

In accordance with rules and regulations adopted by the SEC, we have elected to provide our stockholders with access to our proxy materials over the Internet. Accordingly, we intend to send a Notice of Internet Availability of Proxy Materials (the “Notice”) on or about April 13, 2022 to most of our stockholders who owned our common stock at the close of business on March 30, 2022. The Notice includes instructions on how you can access our Annual Report and Proxy Statement and other soliciting materials on the Internet or, if you wish, request a printed set of such materials, a list of the matters to be considered at the 2022 Annual Meeting, and instructions as to how your shares can be voted. Most stockholders will not receive a printed copy of the proxy materials unless they request one in the manner set forth in the Notice. This permits us to conserve natural resources and reduces our printing costs, while giving stockholders a convenient and efficient way to access our proxy materials and vote their shares.

We will bear the expense of soliciting proxies. In addition to these proxy materials, our directors and employees (who will receive no compensation in addition to their regular salaries) may solicit proxies in person, by telephone or by email. We will reimburse Intermediaries for reasonable charges and expenses incurred in forwarding solicitation materials to their clients.

 

		Voting by Internet. You may submit your proxy over the Internet by following the instructions provided in the Notice, or, if you receive printed proxy materials, by following the instructions for Internet or telephone voting provided with your proxy materials and on your proxy card or voting instruction form.
		Voting by telephone. You may submit your proxy by telephone by following the instructions provided in the Notice, or, if you receive printed proxy materials, by following the instructions for Internet or telephone voting provided with your proxy materials and on your proxy card or voting instruction form.
		Voting by mail. If you receive printed proxy materials, you may submit your proxy by mail by completing, signing, dating and returning your proxy card or, for shares held beneficially in street name, by following the voting instructions included by your broker or other Intermediary. If you provide specific voting instructions, your shares will be voted as you have instructed.

Questions and Answers About the Annual Meeting and Voting

Who can vote at the meeting?

 

 

 

 

72    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Annual Meeting Information  |  Questions and Answers About the Annual Meeting and Voting

 

How can I attend and vote at the meeting?

 

 

 

 

How can I ask questions during the meeting?

 

 

 

 

How can I vote my shares without attending the meeting?

 

 

 

 

Why did I receive a Notice of Internet Availability of Proxy Materials in the mail instead of a full set of proxy materials?

 

 

 

 

AMYRIS, INC. 2022 PROXY STATEMENT    73

---

Table of Contents

Annual Meeting Information  |  Questions and Answers About the Annual Meeting and Voting

 

 

Why did I receive a full set of proxy materials in the mail instead of a Notice of Internet Availability of Proxy Materials?

 

 

 

 

Can I vote my shares by filling out and returning the Notice?

 

 

 

 

What is a quorum?

 

 

 

 

What proposals will be voted on at the meeting?

 

 

 

 

74    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

Annual Meeting Information  |  Questions and Answers About the Annual Meeting and Voting

 

 

How does the Board recommend I vote on the proposals?

 

 

 

 

What happens if I do not give specific voting instructions?

 

 

 

 

Which proposals are considered “routine” and which are considered “non-routine”?

 

 

 

 

How are votes counted?

 

 

 

 

AMYRIS, INC. 2022 PROXY STATEMENT    75

---

Table of Contents

Annual Meeting Information  |  Questions and Answers About the Annual Meeting and Voting

 

 

What is the vote required to approve each of the Board’s proposals?

 

 

 

 

How can I revoke my proxy and change my vote after I return my proxy card?

 

 

 

 

How can I find out the voting results of the meeting?

 

 

 

 

76    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

		Other Matters

 

Householding of Proxy Materials

The SEC has adopted rules that permit companies and Intermediaries to satisfy the delivery requirements for Proxy Statements and Annual Reports, including Notices of Internet Availability of Proxy Materials, with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials (the “Notice”) or other proxy materials addressed to those stockholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.

A number of brokers with account holders who are Amyris stockholders may be “householding” our proxy materials. A single copy of the Notice or other proxy materials may be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be “householding” communications to your address, “householding” will continue until you are notified otherwise or you submit contrary instructions. If, at any time, you no longer wish to participate in “householding” and would prefer to receive a separate Notice or other proxy materials, you may: (1) notify your broker; (2) direct your written request to Amyris Investor Relations at 5885 Hollis Street, Suite 100, Emeryville, California 94608 or to investor@amyris.com; or (3) contact Amyris Investor Relations at (510) 740-7481. Stockholders who currently receive multiple copies of the Notice or other proxy materials at their addresses and would like to request “householding” of their communications should contact their brokers or Amyris Investor Relations at the address or telephone number above. In addition, we will promptly deliver, upon written or oral request to the address or telephone number above, a separate copy of the Notice or other proxy materials to a stockholder at a shared address to which a single copy of such documents was delivered.

Available Information

We will provide to any stockholder entitled to vote at our 2022 Annual Meeting of Stockholders, at no charge, a copy of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Form 10-K”), including the financial statements and the financial statement schedules contained in the Form 10-K. We make our Annual Reports on Form 10-K, as well as our other SEC filings, available free of charge through the investor relations section of our website located at https://investors.amyris.com/annual-reports as soon as reasonably practicable after they are filed with or furnished to the SEC. Information contained on or accessible through our website or contained on other websites is not deemed to be part of this Proxy Statement. In addition, you may request a copy of the Form 10-K by sending an e-mail request to Amyris Investor Relations at investor@amyris.com, calling (510) 740-7481, or writing to Amyris Investor Relations at 5885 Hollis Street, Suite 100, Emeryville, California 94608.

Stockholder Proposals to be Presented at Next Annual Meeting

Stockholder proposals may be included in our Proxy Statement for an annual meeting so long as they are provided to us on a timely basis and satisfy the other conditions set forth in SEC regulations under Rule 14a-8 regarding the inclusion of stockholder proposals in company-sponsored proxy materials. For a stockholder proposal to be considered for inclusion in our Proxy Statement for the annual meeting to be held in 2023, we must receive the proposal at our principal executive offices, addressed to the Secretary, no later than December 14, 2022. To comply with the universal proxy rules (once effective), stockholders who intend to solicit proxies in support of director nominees other than the company’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than March 3, 2023. In addition, a stockholder proposal that is not intended for inclusion in our Proxy Statement under Rule 14a-8 may be brought before the 2023 Annual

 

AMYRIS, INC. 2022 PROXY STATEMENT    77

---

Table of Contents

Other Matters  |  Forward-Looking Statements

 

Meeting so long as we receive information and notice of the proposal in compliance with the requirements set forth in our bylaws, addressed to the Secretary at our principal executive offices, not earlier than February 11, 2023 nor later than March 13, 2023.

The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment.

By Order of the Board of Directors

Nicole Kelsey		Amyris, Inc.
Chief Legal Officer and Secretary April     , 2022		5885 Hollis Street, Suite 100 Emeryville, California 94608

Forward-Looking Statements

This Proxy Statement contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These statements may be identified by their use of such words as “expects,” “anticipates,” “intends,” “hopes,” “believes,” “could,” “may,” “will,” “projects”, “continue”, and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements. We caution that a variety of factors, including but not limited to the following, could cause our results to differ materially from those expressed or implied in our forward-looking statements: our cash position and ability to fund our operations; difficulties in predicting future revenues and financial results; the potential loss of, or inability to secure relationships with, key distributors, customers or partners; the ongoing impact of the COVID-19 pandemic on our business, financial condition and results of operations; our lack of revenues generated from the sale of our renewable products; our inability to decrease costs to enable sales of our products at competitive prices; delays in production and commercialization of products due to technical, operational, cost and counterparty challenges; challenges in developing a customer base in markets with established and sophisticated competitors; and other risks detailed from time to time in filings we make with the Securities and Exchange Commission, including our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Except as required by law, we assume no obligation to update any forward-looking information that is included or incorporated by reference in this Proxy Statement, whether as a result of new information, future events, or otherwise.

 

78    AMYRIS, INC. 2022 PROXY STATEMENT

---

Table of Contents

		Appendix A — Certificate of Amendment of Restated Certificate of Incorporation

 

Amyris, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”),

DOES HEREBY CERTIFY THE FOLLOWING:

FIRST: That the name of the Corporation is Amyris, Inc.

SECOND: That the date on which the Certificate of Incorporation of the Corporation was originally filed with the Secretary of State of Delaware is April 15, 2010 under the name Amyris Biotechnologies, Inc.

THIRD: That, at a meeting of the Board of Directors of the Corporation (the “Board”), the Board duly adopted resolutions setting forth the following proposed amendment of the Restated Certificate of Incorporation of the Corporation, as amended, declaring said amendment to be advisable and directing the Corporation to submit said amendment to the next annual meeting of the stockholders of said Corporation for consideration thereof, and that, thereafter, pursuant to such resolutions, the Corporation submitted the amendment to the stockholders of the Corporation at such annual meeting of the stockholders of the Corporation duly called and held upon notice in accordance with Section 222 of the Delaware General Corporation Law at which meeting the necessary number of shares as required by statute were voted in favor of said amendment:

Section 1 of Article IV of the Corporation’s Restated Certificate of Incorporation is hereby amended to read in its entirety as follows:

“1. Total Authorized. The total number of shares of all classes of stock that the corporation has authority to issue is Five Hundred Fifty-Five Million (555,000,000) shares, consisting of two classes: Five Hundred Fifty Million (550,000,000) shares of Common Stock, $0.0001 par value per share, and Five Million (5,000,000) shares of Preferred Stock, $0.0001 par value per share.”

FOURTH: That said amendment was duly adopted in accordance with the provisions of Section 242 of the Delaware General Corporation Law.

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment of the Restated Certificate of Incorporation to be signed by its Chief Legal Officer and Secretary this     day of May, 2022 and the foregoing facts stated herein are true and correct.

 

 

AMYRIS, INC. 2022 PROXY STATEMENT    A-1

---

Table of Contents

P.O. BOX 8016, CARY, NC 27512-9903 YOUR VOTE IS IMPORTANT! PLEASE VOTE BY: INTERNET Go • To: www.proxypush.com/AMRS • Cast your vote online • Have your Proxy Card ready Follow the simple instructions to record your vote PHONE Call 1-866-834-5365 • • Use any touch-tone telephone • Have your Proxy Card ready Follow the simple recorded instructions MAIL • • Mark, sign and date your Proxy Card Fold and return your Proxy Card in the postage-paid envelope provided “ALEXA, VOTE MY PROXY” • • Open Alexa app and browse skills Search “Vote my Proxy” • Enable skill To attend the meeting, you must pre-register at www.proxydocs.com/AMRS Amyris, Inc. Annual Meeting of Stockholders For Stockholders as of March 30, 2022 TIME: Friday, May 27, 2022 2:00 PM, Pacific Time PLACE: Virtual Meeting: Please visit www.proxydocs.com/AMRS for registration details. This proxy is being solicited on behalf of the Board of Directors The undersigned hereby appoints John Melo and Nicole Kelsey (the “Named Proxies”), and each or either of them, as the true and lawful attorneys of the undersigned, with full power of substitution and revocation, and authorizes them, and each of them, to vote all the shares of capital stock of Amyris, Inc. which the undersigned is entitled to vote at said meeting and any adjournment thereof upon the matters specified and upon such other matters as may be properly brought before the meeting or any adjournment thereof, conferring authority upon such true and lawful attorneys to vote in their discretion on such other matters as may properly come before the meeting and revoking any proxy heretofore given. THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO DIRECTION IS GIVEN, SHARES WILL BE VOTED IDENTICAL TO THE BOARD OF DIRECTORS RECOMMENDATION. This proxy, when properly executed, will be voted in the manner directed herein. In their discretion, the Named Proxies are authorized to vote upon such other matters that may properly come before the meeting or any adjournment or postponement thereof. You are encouraged to specify your choice by marking the appropriate box (SEE REVERSE SIDE) but you need not mark any box if you wish to vote in accordance with the Board of Directors’ recommendation. The Named Proxies cannot vote your shares unless you sign (on the reverse side) and return this card. PLEASE BE SURE TO SIGN AND DATE THIS PROXY CARD AND MARK ON THE REVERSE SIDE

---

Table of Contents

Amyris, Inc. Annual Meeting of Stockholders Please make your marks like this: X THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR ALL DIRECTOR NOMINEES AND FOR PROPOSALS 2 AND 3. BOARD OF DIRECTORS PROPOSAL YOUR VOTE RECOMMENDS 1. Election of three Class III Directors nominated by the Board to serve for a three-year term. FOR WITHHOLD 1.01 John Doerr FOR #P2# #P2# 1.02 Ryan Panchadsaram FOR #P3# #P3# 1.03 Lisa Qi FOR #P4# #P4# FOR AGAINST ABSTAIN 2. Ratification of the appointment of Macias Gini & O’Connell LLP as Amyris’ independent registered FOR public accounting firm for the fiscal year ending December 31, 2022. #P5# #P5# #P5# 3. Approval of an amendment to Amyris’ Certificate of Incorporation to effect an increase in the total FOR authorized shares. #P6# #P6# #P6# 4 To act upon such other matters as may properly come before the Annual Meeting or any adjournments or postponements thereof. To attend the meeting, you must pre-register at www.proxydocs.com/AMRS Authorized Signatures—Must be completed for your instructions to be executed. Please sign exactly as your name(s) appears on your Proxy Card. If held in joint tenancy, all persons should sign. Trustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the Proxy Card. Signature (and Title if applicable) Date Signature (if held jointly) Date